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 Approximately one-eighth of women in the United States go into pre-term labor and are 
prescribed synthetic glucocorticoids (GCs) to minimize complications of prematurity and 
increase the likelihood of fetal survival. Despite these beneficial effects, GCs have permanent 
negative consequences on brain development, which may lead to neuropsychiatric disorders such 
as post-traumatic stress disorder, depression and anxiety later in life. The mechanistic bases for 
these GC induced neurodevelopmental changes are unknown. Therefore, we used neural 
progenitor/stem cells isolated from the cerebral cortex (CC-NPSCs) or hypothalamus (HT-
NPSCs), to identify novel mechanisms for how GCs could impact the developing brain.  
In CC-NPSCs, we identified a role for Caveolin-1 (Cav-1) in mediating crosstalk 
between the rapid and genomic actions of the glucocorticoid receptor (GR). Using Cav-1 KO 
mice, we identified approximately 100 genes that are differentially responsive to GC treatment in 
the Cav-1 KO CC-NPSCs. Therefore, we established a role for Cav-1 in regulating the genomic 
action of GR. Phosphorylation of the GR impacts its genomic action, and GC-induced 
phosphorylation of GR at Serine 211, but not Serine 226 was altered in the Cav-1 KO.  Using 
chromatin immunoprecipitation experiments, we determined that pSer211-GR recruitment to 
certain target genes was altered in Cav-1 KO CC-NPSCs. Therefore, we propose that Cav-1 
dependent GC action impacts hormone regulated transcription through its influence on site-
specific phosphorylation of GR.  
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RNA-Seq analysis of male/female HT-NPSCs treated with Dexamethasone (Dex, a 
synthetic GC) identified sexually dimorphic GR regulated genes. Using candidates from the 
RNA-Seq analysis, we identified GC mediated programming effects on Fkbp5 and H19. In 
response to a previous exposure to Dex, female, but not male, HT-NPSCs re-treated with Dex 
have attenuated induction of the Fkbp-5 gene. H19 was similarly GC-regulated in both male and 
female, but previous treatment with Dex resulted in GC-mediated repression instead of 
activation. Since H19 harbors a miRNA implicated in regulation of stem cell proliferation, 
changes in its regulation may be a contributing factor in the altered proliferative response to Dex 
seen in pre-treated HT-NPSCs. Therefore, HT-NPSCs exposed to Dex exhibit sexually 
dimorphic and long lasting changes in gene expression and NPSC function. 
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1.0  INTRODUCTION 
1.1 GLUCOCORTICOIDS AND THE GLUCOCORTICOID RECEPTOR 
Glucocorticoids (GCs) are steroid hormones that serve a variety of roles to regulate homeostasis. 
For example, GCs serve a critical role in the body’s stress response and also in regulating 
circadian rhythms. GCs bind to two different nuclear receptors, the glucocorticoid receptor (GR) 
and the mineralocorticoid receptor (MR). GR is widely expressed throughout the body whereas 
MR expression, although expressed in the brain, is generally limited to organs or tissues that are 
aldosterone sensitive such as the kidney, colon, and salivary glands (1).  
Within the brain, GR is expressed in all regions whereas MR expression is limited to the 
hippocampus and limbic regions (2). Although the MR is activated by the mineralocorticoid 
aldosterone to aid in salt and water balance, the majority of receptors are bound to physiological 
GCs—cortisol in humans, corticosterone in rodents (3). Interestingly, only the GR binds to 
synthetic GCs such as Dexamethasone (Dex) and Betamethasone (Beta) (4), but the MR binds 
cortisol with much higher affinity than the GR, Kd: 0.5 nM versus 5.0nM respectively (5). Since 
MR has a higher affinity for cortisol, under resting conditions in the brain the MR and not GR is 
primarily occupied by cortisol. However, under stressful conditions when plasma cortisol levels 
rise, the occupation of GR increases (6). This interaction between MR/GR and is thought to help 
regulate the stress response with MR controlling early arousal and reaction and GR to resolve the 
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stress response and aid in processing and storage of memories related to the situation (5). Some 
have suggested that the balanced activation of MR and GR is critical for maintenance of mental 
health. For example, in response to early life stress, epigenetic modifications of the GR can occur 
leading to changes in its expression and consequent alterations in stress response and cognitive 
performance later in life (5).  
GR action is essential for a variety of physiological processes including development, 
metabolism, central nervous system function, hypothalamic pituitary adrenal (HPA) axis 
regulation (see §3.1.1), and immune response (7, 8). For example, in the cardiovascular system 
GCs regulate blood pressure homeostasis by inhibiting the production of vasodilators like nitric 
oxide (9). GCs also regulate energy homeostasis through the regulation of processes such as 
gluconeogenesis in the liver to increase glucose levels in response to exercise or stress (9). GR is 
also implicated in proper embryonic development. For example, GR null mice have abnormal 
lung development and die shortly after birth from respiratory failure (9). GCs are also implicated 
in proper development of the brain through processes such as enhancing the maturation of 
neurons (2), although at high doses they can have negative consequences (see §1.3).  
The GR belongs to the Type 1 group of nuclear receptors (NRs) along with the 
mineralocorticoid, androgen, estrogen and progesterone receptors (10). NRs are a large family of 
ligand activated transcription factors that regulate a variety of cellular processes through various 
mechanisms. These mechanism include post-translational modification of the NRs, ligand 
dependent/independent actions, and genomic and/or rapid signaling (11). The GR can signal 
through both genomic (discussed below) and rapid signaling pathways (discussed in §2.1.2). In 
genomic signaling, the inactive GR resides within the cytoplasm of the cell bound to heat shock 
proteins (hsp90, hsp70, and p23) as well as to the immunophilins FKBP51 and FKBP52 (12). 
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GCs passively diffuse through the cell membrane and bind to the cytoplasmically localized GR 
to cause a conformational change and consequent activation of the receptor. During the 
conformational change, the GR dissociates from the chaperone proteins and two nuclear 
localization sequences are revealed. The GR homodimerizes and then translocates to the nucleus 
where it binds to DNA at GR specific hormone response elements. Each NR binds to its own 
specific DNA sequence called a hormone response element. In the case of the GR, these 
hormone response elements are called GC response elements or GREs. GREs are imperfect 
palindromes that contain two 6 base pair half sites. The homodimer of GR binds in such a 
manner that each half site is bound by one GR (12). Interestingly, these GREs vary between 
different cell types. These different GREs are thought to serve as allosteric regulators of the GR, 
and cause distinct structural changes depending on the cell type, thereby resulting in a discrete 
function (13). In addition, receptor binding is also influenced by baseline (pre-treatment) 
chromatin accessibility. Namely, the majority of GR binding sites are found in pre-existing 
regions of open chromatin (14). Furthermore, the vast majority (~90%) of GREs are found 
further than 5 kilobases away from the transcriptional start site, and approximately 16% can be 
found either 50 kilobases upstream of the transcriptional start site, or 50 kilobases downstream of 
the stop codon (15). Once the receptor is bound to DNA it undergoes additional conformational 
changes to recruit other transcriptional regulators to affect gene transcription. For example, to 
exert repressive effects on transcription, after binding of the GR to DNA co-repressors such as 
nuclear receptor co-repressor (NCoR) and the silencing mediator of retinoic acid and thyroid 
hormone receptor (SMRT) may be recruited. The presence of these co-regulators then triggers 
the recruitment histone deacetylases to trigger changes in chromatin and consequent gene 
repression (9). There are also examples where GR may interact with other transcription factors to 
 3 
regulate gene transcription without direct DNA binding. Within the liver, these transcription 
factors include AP-1, nuclear factor-κB, signal transducers and activators of transcription 
(STAT) family members and CCAAT-enhancer-binding proteins (C/EBP) family members. In 
fact, transcriptional activation of the Haptoglobin gene is mediated by GR interacting directly 
with STAT3 and C/EBPβ (16).  
The GR shares several similar structural features with other NR as shown in Figure 1. 
The amino-terminal domain (NTD) is not highly conserved, but contains the activation function-
1 (AF-1) domain. The AF-1 domain is critical for transcriptional activation. In fact, when 
separated from the rest of the receptor, the AF-1 domain is capable in activating transcription in 
a ligand independent manner (11). The AF-1 region is a critical site for post-translational 
modifications including phosphorylation, sumoylation, and ubiquitination that control receptor 
transcriptional activity and stability. The DNA binding domain or DBD is the most highly 
conserved domain. The DBD facilitates DNA binding to specific sequences through two zinc 
finger motifs. Notably, a single amino acid change within certain regions of the DBD can alter 
the receptor’s ability to bind to GREs versus estrogen receptor response elements (11). The hinge 
(H) region is poorly conserved between receptors but its flexibility allows for the receptor to 
adopt different conformations. The hinge region also contains a nuclear localization sequence 
that aids in receptor shuttling from the cytoplasm to the nucleus. The ligand-binding domain 
(LBD) is a multifunctional region and has three distinct roles—ligand binding, receptor 
dimerization and supports transcriptional activation via the AF-2 domain. GCs bind the GR 
within a hydrophobic pocket in the LBD. The LBD also contains the AF-2 region which aids in 
ligand mediated activation of the receptor. In addition, the LBD serves as a docking point for the 
formation of GR homodimers. For other non-steroid hormone members of the NR superfamily, 
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the LBD can facilitate the formation of heterodimers with the retinoid X receptor. The LBD also 
serves as a point of interaction with transcriptional corepressors. Finally, the LBD allows GR and 
other Type I NRs to interact with heat-shock proteins in the cytoplasm (11).  
The GR can have various post-translational modifications such as phosphorylation or 
sumolyation that impact its transcriptional activity (8). In fact, different phosphorylation patterns 
within the AF-1 region can dictate which target genes will be bound by GR (17). For example, in 
cells containing a GR that is unable to be phosphorylated at S404, microarray studies indicate 
major alterations in global transcriptional responses to hormone ultimately resulting in activation 
of different signaling pathways and changes in GC dependent cell death (18). A variety of 
kinases can phosphorylate the GR at different serine residues including cyclin-dependent 
kinases, mitogen-activated protein kinases, and glycogen synthase kinase (GSK) 3β (8, 18). 
Phosphorylation of the GR is implicated in a variety of human diseases and also in an 
individual’s response to treatment. For example, in asthma patients increased phosphorylation of 
the GR at S134 was associated with a decreased anti-inflammatory benefit of inhaled GCs (12). 
GR phosphorylation at S211 is associated with activation of gene expression whereas pSer226-
GR is associated with transcriptional repression. Therefore, a ratio between the two GR 
phosphoisoforms can be used as a readout of transcriptional activity. In fact, alterations of this 
ratio in the brain are associated with depression. Furthermore, in women who report heightened 
levels of depression, anxiety and stress tend to have increased levels of nuclear pSer226-GR 
(19). 
Within the AF-1 region of the GR, there are three major phosphorylation sites, S203, 
S211, and S226 (Figure 2). The GR can be phosphorylated at these sites under both basal 
conditions (S203 and S226) and in the presence of agonists (S211) (17). Furthermore, different 
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phospho-isoforms of the GR are localized to different regions of the cell. For, example, pSer211-
GR and pSer226-GR are found in the nucleus of the cell whereas the pSer203-GR form is found 
predominantly in the cytoplasm (17). Different phospho-isoforms of the receptor also have 
differences in the kinetics of recruitment to the regulatory regions of different target genes. For 
example, as shown by chromatin immunoprecipitation experiments, maximal recruitment of 
pSer226-GR occurs within 15 minutes whereas maximal pSer211-GR does not occur until 45 
minutes after initial treatment (17).  
 
Figure 1. Schematic of the GR highlighting major sites of phosphorylation. 
 
Disruptions in phosphorylation of the receptor can result in altered transcriptional 
responses leading to changes in cell function (17, 18). For example, phosphorylation of the GR at 
S404 by GSK3β results in diminished GR function and increased degradation of the receptor. In 
cells containing a GR unable to be phosphorylated at S404, there are global alterations in 
transcriptional response resulting in overall changes in GC induced apoptosis (18). In addition, 
treatment with growth factors such as brain derived neurotrophic factor (BDNF) concurrent with 
GC treatment results in distinct patterns of phosphorylation and gene transcription. For example, 
treatment with BDNF causes phosphorylation of the GR at S155 and S287 and results in the 
regulation of a distinct subset of genes (20).  
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1.2 CLINICAL USAGE OF GLUCOCORTICOIDS  
GCs are commonly used as treatment for a multitude of illnesses such as asthma, allergies, 
rheumatoid arthritis, multiple sclerosis, and type 1 diabetes mellitus (8). Given the potent anti-
inflammatory actions of GCs, they are commonly used to treat a wide variety of inflammatory 
diseases including conjunctivitis, asthma, eczema, and rheumatoid arthritis (9).  GCs also have a 
wide variety of immunosuppressive effects. For example, GCs suppress both dendritic cell 
maturation and migration of neutrophils. Consequently, GCs are widely used for 
immunosuppression in organ transplant patients (9). Given their anti-proliferative and anti-
angiogenic properties, GCs may also be used to treat some forms of cancer (9). 
Importantly, synthetic GCs are prescribed to women in or at risk for pre-term labor to 
decrease the complications of prematurity, particularly to prevent respiratory distress syndrome 
and intraventircular hemorrhage in the fetus (21). The lungs are one of the last major organ 
systems to develop and treatment with GCs speeds up lung maturation by increasing the 
production of surfactant therefore, decreasing the risk for respiratory distress syndrome. GR can 
also mediate maturation and differentiation within the developing lung, particularly within the 
mesenchyme derived cells (22). Treatment with GCs also decreases the risk for intraventricular 
hemorrhage by stabilizing the germinal matrix, an area of the brain that is heavily vascularized 
and vulnerable to injury (21). GCs can also be used during the fetal period to prevent virilization 
of female infants with congenital adrenal hyperplasia and to prevent inflammation during surgery 
to correct congenital cardiac defects (23, 24).  
Clinically, there are two classes of synthetic GCs that are used during the fetal period, 
Dex and Beta. Although Dex and Beta are very similar structurally, varying only in the position 
of a methyl group, they have different dosing schedules and varying potencies. For example, 6 
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mg Dex are given four times with 12 hour in between in each dosing whereas 12mg of Beta are 
given twice 24 hours apart (25). Dex and Beta also have similar potencies for activating genomic 
GR, although Dex has a 5-fold greater potency for activating the rapid action of GR (26). Head 
to head comparisons of the two GCs in developing mice indicated that overall Beta produced a 
greater pulmonary benefit without retarding growth (27).  
1.3 IMPLICAITONS FOR USE OF GLUCOCORTICOIDS DURING BRAIN 
DEVELOPMENT  
Unlike naturally secreted GCs, clinically relevant synthetic GCs are not inactivated by enzymes 
found in the placenta (28). Furthermore, GCs easily cross the blood brain barrier via simple 
diffusion (4). Since GCs are used during the fetal period while the brain is still developing, it is 
therefore not surprising that data from both human and animal models indicates that GC 
treatment results in long lasting alterations in the central nervous system. 
In mouse models, treatment with GCs results in decreased proliferation in the 
hippocampus and cerebral cortex and impaired cognitive function (4, 29). Studies in rats indicate 
that prenatal treatment with Dex, results in impaired radial migration in the cerebral cortex (30). 
Sheep born at term but treated prenatally with GCs have deficits in myelination and smaller brain 
size that persists into adulthood (4). Furthermore, studies in non-human primates indicate that 
term born animals treated prenatally with GCs have smaller hippocampi and impaired 
differentiation of neurons (reviewed in (4)). In the adult rat hippocampus, stress or exogenous 
treatment with the GC corticosterone results in diminished neurogenesis and enhanced 
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differentiation of oligodendrocytes (31). Therefore, studies in a variety of model systems have 
underscored the negative effects of GCs on the central nervous system.  
In humans, prenatal usage of GCs is associated with decreased cerebral cortex surface 
area, attention deficits, decreased cognitive performance, and increased aggressive and 
destructive behaviors (reviewed in (4)). A recent study in term born infants indicated that 
children exposed prenatally to synthetic GCs grow up to have significant thinning of the cerebral 
cortex, particularly in the rostral anterior cingulate cortex. Furthermore, thinner cortices in the 
left rostral anterior cingulate cortex were associated with increased affective behaviors (32). 
Children, particularly females, treated prenatally and born at term also have altered stress 
reactivity and may therefore be more vulnerable to stress related neuropsychiatric disorders (33).  
Studies in children treated postnatally with GCs give conflicting results regarding changes in 
overall brain structure. Cheong et al report that adolescents treated postnatally with Dex, had 
smaller brains overall, particularly in the white matter, thalami, and basal ganglia and no changes 
in gray matter (34). In contrast, a smaller study reported a 35% reduction in total gray matter and 
no difference in white matter (35). The aforementioned studies took place over a decade apart in 
two different countries, so variability between the two may be related to differences in cohort 
and advances in medical technology. Regardless, postnatal and prenatal treatment with Dex 
clearly results in overall changes in brain structure.  
While the mechanism(s) responsible for these alterations are not well established, they 
may involve changes in neural progenitor/stem cell proliferation and/or differentiation thereby 
disrupting the development of neuronal circuits essential for higher order cognitive or behavioral 
function. 
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1.4 STUDYING THE IMPACT OF GLUCOCORTICOIDS ON BRAIN 
DEVELOPMENT USING A NEUROSPHERE MODEL  
Studies examining GC effects on neural progenitor-stem cell (NPSC) function in a variety of 
experimental systems uncovered a number of affected pathways and signaling molecules. For 
example, in rat embryonic neural stem cells, GCs decreased proliferation by enhanced 
degradation of the cell cycle regulator, Cyclin-D1 (36). In the mouse cerebellum, neonatal 
treatment with Dex increased apoptosis of the neural progenitor cells within the extra granule 
cell layer and decreased overall numbers of internal granule layer neurons (37). GC effects on 
the differentiation of NPSCs are varied and conflicting; reduced differentiation of glial cells by 
GCs was reported in mesencephalic NPSCs and adult rat hippocampal progenitor cells while 
GCs increased differentiation of glia in human NPSC cultures (38-40).  
In these studies, NPSCs were cultured as 3-dimensional neurospheres (Figure 3). NPSCs 
were isolated from E14.5 mouse cerebral cortex (§2) or hypothalamus (§3). We chose to use 
E14.5 as there are detectable levels of GR expression (41), but the embryo is still in a hormone-
naïve state. In addition, there is significant expansion of NPSCs at E14.5 therefore increasing the 
number of cells available to harvest. To maintain their undifferentiated state, neurospheres are 
cultured in the presence of epidermal growth factor (EGF) and/or fibroblast growth factor-1 
(FGF-1) (Figure 3). Cells are broken up and replated or passaged (P) once per week and the 
number of passages denoted by a number i.e. P1 or P3.  EGF and FGF are crucial for promoting 
renewal and expansion of the NPSC, and it is important to note that cells responsive to these 
growth factors maintain the ability to differentiate into neurons, astrocytes and oligodendrocytes 
(42, 43). The advantage of this model lies in the ability of neurospheres to properly recapitulate 
the in vivo differentiation order of neurons and glia under in vitro conditions (44, 45) (Figure 3). 
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Figure 2. Schematic of neural progenitor/stem cell culture. 
Cells cultured in the presence of EGF and FGF-1 form 3D balls of cells called neurospheres. 
Cells cultured under adherent conditions on Poly-D-Lysine and laminin treated glass coverslips 
without EGF and FGF-1 differentiate in neurons, astrocytes, and oligodendrocytes. Neurospheres 
can be passaged weekly at least five times.  
 
 
 
 11 
1.5 GOALS OF DISSERTATION 
The beneficial nature of GCs in decreasing the negative consequences of prematurity (i.e. 
respiratory distress syndrome, intraventricular hemorrhage) is undisputed. However, in multiple 
studies including in vitro analysis of NPSCs, animal models, and human studies all indicate 
permanent negative consequences on the biology of NPSCs (36-40), gross anatomy of different 
structures of the brain (cerebral cortex, hippocampus) (4), and changes in behavior and stress 
reactivity (32, 33). Although we currently do not have a clear mechanism for the nature of these 
deficits, one potential way to abrogate these negative consequences while maintaining the 
beneficial nature of glucocorticoids is to develop a better understanding of the molecular changes 
occurring at the level of NPSCs. Therefore, this study takes a genome-wide approach to analyze 
the impact of the synthetic and clinically relevant GC, Dex, on gene expression and biology of 
NPSCs from the cerebral cortex and the hypothalamus.  
In Chapter 2, using NPSCs isolated from E14.5 mouse cerebral cortex, we identified a 
new role for Caveolin-1 (Cav-1) in mediating cross talk between the genomic and rapid actions 
of the GR. Loss of Cav-1 resulted in altered regulation of a select group of target genes (~100 
genes/14,000 analyzed), many of which are implicated in a variety of processes related to NPSC 
biology (i.e. proliferation and migration). These changes in gene expression may be the result of 
changes in phosphorylation of the GR at Serine 211 and altered recruitment of the GR to the 
regulatory regions of target genes. Better understanding of the impact of genomic, rapid, and the 
cross talk between the two may indicate which GR pathways are the underlying causes of altered 
neural development, possibly leading to more directed therapies.  
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In Chapter 3, we utilized NPSCs isolated from the hypothalami of male or female E14.5 
mice. Using RNA-Seq analysis, we uncovered sexually dimorphic patterns of Dex-regulated 
gene expression. Furthermore, deeper analysis of select target genes uncovered by RNA-Seq 
demonstrated that certain target genes have long lasting, sexually dimorphic changes in 
transcriptional responses if previously treated with Dex. Fkbp-5 was found to be less induced in 
specifically female cells previously treated with Dex. In contrast, the large intergenic non-coding 
RNA, H19, did not have long lasting sexually dimorphic changes in transcriptional response, but 
did demonstrate an reversal of GC regulated gene expression. In both male and female cells, a 
previous treatment with Dex resulted in a future repression of H19 gene expression instead of the 
expected gene activation. H19 also harbors a micro-RNA implicated in proliferation of stem cells 
(46), and changes in H19 regulation may underlie the altered proliferative response seen in HT-
NPSCs previously exposed to Dex. Therefore, Dex treatment can cause sexually dimorphic, long 
lasting changes in gene expression. Improved understanding of which genes have long term 
alterations and their role in neural development and physiology, as well as differences between 
the sexes may lead to more directed, or potentially sex-specific therapies.  
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2.0  CAVEOLIN-1 REGULATES THE GENOMIC ACTION OF THE 
GLUCOCORTICOID RECEPTOR IN NEURAL STEM CELLS  
2.1 INTRODUCTION 
2.1.1 Development of the Cerebral Cortex 
In early development, the neuroepithelium (NE) derives from the ectoderm and gives rise to 
neurons and glia (47). Prior to the onset of neurogenesis at E12 in the mouse, the cells of the NE 
divide symmetrically to increase their total numbers (44, 48). At the onset of neurogenesis, NE 
cells begin to acquire gliogenic features and express astrocytic markers such as astrocyte- 
specific glutamate transporter (GLAST), glial fibrillary acidic protein (GFAP) and intermediate 
filament proteins such as nestin and vimentin, and are considered to be radial glia (47).  
During the development of the cerebral cortex (CC), the radial glial (RG) cells initially 
undergo asymmetric divisions, which result in more RG as well as neurons or intermediate 
progenitor cells (47). RG extend from the ventricular to pial surface and serve as “tracks” for 
neurons to “follow” to their final destination in the CC (49). RG are also capable of generating 
neurons, neuronal precursors, and two types of glia, astrocytes, and oligodendrocytes. 
Consequently, RG are considered to be (at least in rodents) the main source of these cell types in 
the cortex (49). Right before birth, a competency change occurs in the radial glial allowing 
differentiation of astrocytes, then oligodendrocytes (47). Astrocytes are the most numerous type 
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of glial cell and perform a variety of functions including control of blood flow, movement of 
nutrients, formation of proper synapses and removal of excess neurotransmitters (50, 51). 
Oligodendrocytes produce myelin, which wraps around the neuronal axons and is essential for 
the rapid conduction of an action potential (50). 
The CC is the largest region of the human brain and regulates higher order abilities, 
cognition, and emotion (52). Given the complexity and importance of the CC it is not surprising 
that alterations in its development can contribute to neurodevelopmental diseases such as autism 
spectrum disorders, schizophrenia, and major depressive disorder (52, 53). In fact, high levels of 
GC hormones during the fetal period are also linked to the acquisition of neurodevelopmental 
disorders.  For example, maternal stress resulting in elevated levels of GCs during pregnancy is 
implicated in the child’s future development of schizophrenia, anxiety, depression, autism 
spectrum disorders, and attention deficit hyperactivity disorder (reviewed in: (54)). Furthermore, 
treatment with synthetic GCs to reduce complications of prematurity is also associated with 
increased affective behaviors and predisposition to development of neuropsychiatric disorders 
(see §1.3). Therefore, exposure of the developing CC to high doses of GC may contribute to the 
development of future disease.  
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2.1.2 GR Signaling in CC-NPSCs  
In CC-NPSCs, GC can act through two signaling pathways via the GR, a member of the nuclear 
receptor superfamily of transcription factors (5, 7). In classical or genomic signaling, binding of 
ligand results in GR translocation to the nucleus where it can either activate or repress 
transcription of target genes (Figure 3, §1.1) (55). 
 
Figure 3. Schematic of genomic GR signaling. 
1. GCs passively diffuse through the cell membrane and bind to the GR. 2. Binding of GC to the 
GR results in its activation and dissociation from associated heat shock proteins (HSP). 3. The 
activated GR monomer dimerizes and translocates to the nucleus where it regulates gene 
transcription either by direct binding to DNA (4.) or by interacting with other transcription 
factors (5.) 
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In contrast, rapid or non-classical signaling involves a plasma membrane associated GR 
that is capable of activating kinases, such as mitogen activated protein kinase (MAPK) (Figure 
4). These kinases can then influence GR transcriptional response through direct modification of 
the receptor or its associated transcriptional coregulators (56). Although both rapid and genomic 
GR signaling operates in NPSCs (29), the degree of interaction between the two pathways, and 
the how they intersect to influence GC effects on NPSC biology, are unknown.  
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 Figure 4. Schematic of rapid GR signaling. 
1. GCs activate a membrane localized GR interacting with Caveolin-1 (Cav-1). 2. Upon ligand 
binding, downstream kinases are rapidly activated to impact a variety of cellular responses (3) 
and regulate gene transcription (5). 4. Activation of membrane bound GR is also known to 
inhibit gap junction intercellular communication (GJIC). 6. We hypothesize that the rapid action 
of the GR can impact its genomic action.  
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Studies with other steroid hormone receptors such as the androgen and estrogen receptor 
have revealed mechanisms of cross talk between genomic and rapid actions of the receptors 
(reviewed in (57)). For example, studies using a mutant mouse where the estrogen receptor (ER) 
cannot bind to DNA, stimulation with estrogen and activation of a membrane localized ER 
results in a genomic action, namely by the binding of the NeuroD1 transcription factor to the 
insulin promoter (58). In prostate cancer cells, paxillin is implicated as a liaison between the 
rapid and genomic action of the androgen receptor (59).  
2.1.3 Caveolin-1 Mediates a Wide Variety of Cellular Processes 
Rapid GC signaling in NPSCs that triggers MAPK activation and consequent inhibition of gap 
junction intercellular communication was previously shown by our laboratory to rely on an 
interaction between a plasma membrane bound GR and Cav-1 (29). Cav-1 is the major protein 
subunit of specialized regions of the plasma membrane known as caveolae (60). Cav-1 is 
implicated in a variety of cellular processes including proliferation, differentiation, and cell 
migration. In mouse embryonic stem cells, Cav-1 is implicated as a mediator of cell proliferation 
and loss of Cav-1 via siRNA resulted in lack of a proliferative response when cells were 
stimulated with EGF (61). In contrast, in the adult mouse loss of Cav-1 results in an increase in 
proliferation within the subventricular zone (62). Studies in lung epithelial cells reveal a role for 
Cav-1 in regulating the anti-proliferative action of GCs via its interaction with GR (56). 
Interestingly, Cav-1 is implicated to have both tumor suppressive and tumor supportive roles 
depending on the type of cancer (63). Therefore, the role of Cav-1 in regulating proliferation of 
is very diverse and likely involves many cell specific mechanisms. Cav-1 is also implicated in 
differentiation of NPSCs as Cav-1 Knock-Out (KO) mice have attenuated astroglial 
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differentiation (64) and increased neurogenesis (65). Finally, in mouse embryonic stem cells that 
lack Cav-1, EGF induced cell migration was also significantly decreased, indicating a role for 
Cav-1 in migration of these cells (61). In adult Cav-1 KO animals, the brain tends to be smaller, 
and the mice have alterations in overall activity, impaired motor activity, alterations in gait, 
spatial memory impairment, and increased anxiety (66, 67). Taken together, loss of Cav-1 results 
in wide changes in cellular biology that may lead to abnormalities in the entire animal.  
2.1.4 Rationale and Summary 
Given the role of Cav-1 in mediating the rapid response of GR (29, 56), we set out to examine 
whether Cav-1 could also participate in classical genomic GR signaling and impact the anti-
proliferative response of NPSCs to Dex (Figure 4). Here we show that loss of the Dex-mediated 
anti-proliferative response in NPSCs derived from Cav-1 KO mice is associated with the 
alterations in Dex-induced gene expression of an established negative regulator of the cell cycle 
in NPSCs, serum and glucocorticoid-induced kinase-1, Sgk-1 (68). We also revealed more global 
effects of Cav-1 deletion on the GR transcriptome and uncovered a mechanism for Cav-1 
mediated crosstalk between rapid and genomic GR signaling that impacts site-specific GR 
phosphorylation and chromatin recruitment of GR.  
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2.2 MATERIALS AND METHODS  
Mouse CC-NPSC cultures: NPSCs were derived from embryonic day 14.5 (E14.5) cerebral 
cortex of wild-type C57Bl/6 (C57) or Cav-1 KO mice and grown as three-dimensional 
neurosphere cultures (29). Cells were passaged every seven days and experiments were 
performed at P3 unless indicated otherwise.  
 
CC-NPSC BrdU Assays: P1 neurospheres were cultured for 3 days after passaging before 
replenishment with fresh EGF and FGF-1 (Invitrogen). Approximately 6 h later, cells were 
treated with 100nM Dex (Sigma Chemicals, St. Louis, MO) or vehicle (Ethanol, EtOH). 10uM 
Bromodeoxyuridine (BrdU) (Sigma Chemicals, B-9285) was added for 1 h after 23 h of Dex 
treatment. Neurospheres were then dissociated into single cells and attached to poly-D-lysine 
(PDL) treated coverslips prior to fixation with 4% paraformaldehyde. Fixed cells were processed 
for immunocytochemistry using standard methods. A rat anti-BrdU antibody (Abcam, ab6326) 
was used at 1:500 and Anti-Rat Alexa Flour 488 (Invitrogen, A21208) at 1:1000. Images were 
captured using a Nikon Eclipse E400 Microscope and Photometrics Cool Snap E52 camera. For 
SGK-1 inhibitor experiments, GSK650394 (Tocris Bioscience) was used at a concentration of 
50nM and added coincident with Dex.  
 
Radial Migration Assay: P3 neurospheres were plated on PDL treated 6-well dishes in the 
presence of 100 nM Dex or vehicle 2 days after replenishment with EGF and FGF-1. 
Approximately 10 spheres per well (3 wells per treatment) were imaged at 4, 8, and 24 hours 
after plating/Dex treatment. Images were captured using an Olympus IX71 inverted microscope. 
Following imaging, distance migrated was determined using ImageJ. The distance migrated for a 
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sphere was defined as the distance between the leading edge of the sphere and the furthest 
migrated point, and this measurement was taken at three different locations per sphere, and 
averaged together to determine the distance migrated for an individual sphere.  
 
Differentiation Assay: P1 or P3 neurospheres were treated for 24 hours with 100nM Dex or 
vehicle 2 days after replenishment without EGF and FGF. Following treatment, cells were 
washed once with NeuroCult™ media with differentiation supplement (StemCell Technologies) 
and no growth factors, dissociated, viable cells counted using Trypan Blue staining, and plated at 
a density of 90,000 viable cells/well on coverslips treated with 100ug/mL Poly-D-Lysine and 
15ug/mL laminin. After 1 day of differentiation (1DD) cells were fixed in 4% paraformaldehyde. 
Fixed cells were processed for immunocytochemistry using standard methods. A rabbit anti-
olig2 antibody (Abcam, ab81093) was used at 1:1000 and Anti-rabbit Cy3 at 1:400. A chicken 
anti-nestin antibody (Aves Lab, NES) was used at 1:500 and Anti-chicken Alexa Fluor 488 at 
1:000. Images were captured using a Nikon Eclipse E400 Microscope and Photometrics Cool 
Snap E52 camera. 
 
Microarrays: Total RNA was extracted using Qiagen RNeasy Kit (Qiagen, 74104) from cell 
pellets comprising biologically distinct neurosphere cultures from C57 or Cav-1 KO embryos 
treated with 100 nM Dex or vehicle for 4 h (n=5/treatment condition). Total RNA was further 
processed to determine quality. The 260/280 ratios for all samples was determine to be greater 
than or equal to 1.8 using a NanoDrop 1000 (NanoDrop, Wilmington, GE) and a RIN value of 
greater than or equal to 8.0 as determined using a Bioanalyzer 2100 (Agilent Technologies, Santa 
Clara, CA). Using 500 ng of starting material, samples were then in vitro transcribed using the 
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Ambion MessageAmp Premier Enhanced assay protocol (Ambion Inc, Austin, TX). To confirm 
cRNA diversity, the Bioanalyzer 2100 was used to generate an eletrophoretogram for each 
reaction giving information regarding sample yield, integrity, and size diversity against a 
Universal Human Reference RNA (Stratagene, La Jolla, CA). Fifteen micrograms of purified, 
amplified, biotin labeled cRNA was fragmented and hybridized on to Affymetrix Mouse 
Genome 430A 2.0 arrays (13,687 genes, 22,690 probes; Affymetrix Corp. Santa Clara, CA) for 
18 h.  Washing, staining and scanning of arrays was performed on the Affymetrix Fluidics 
Station 450 and Scanner 3000 immediately after completion of hybridization. The CEL files 
were submitted to GEO (accession # GSE49804). Microarrays were performed by University of 
Pittsburgh genomics core. 
 
Bioinformatic Analysis: Microarray data was first normalized and summarized using the Robust 
Multichip Average (RMA) method (69). Genes represented on the array with multiple probe sets 
were assessed and the probe set with the highest inter-quartile ratio was selected for analysis. 
Genes that were undetectable in all 20 samples analyzed were also removed from the dataset 
leaving 9916 genes for statistical analysis. Using BRB-Array Tools (70), a student’s t-test was 
used to assess differences between Cav-1 KO Dex vs. EtOH, C57 Dex vs. EtOH and Cav-1 KO 
vs. C57 EtOH. A one-way ANOVA (False Discovery Rate, FDR 10%) was performed to 
ascertain genes differentially regulated by Dex treatment in Cav-1 KO versus C57. From this 
dataset networks and biological functions were assed using the Ingenuity Pathway Analysis 
(IPA) software (Ingenuity Systems, Redwood City, CA, USA). Hierarchical clustering figures 
and Venn diagrams are produced in R- Bioconductor.  
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Using the NextBio Research (Cupertino, CA, USA) data-search and analysis engine, a meta-
analysis was performed to compare genes regulated by GC in our studies to 12 other similar 
publically available datasets (Table 1). Within each dataset, a list of differentially expressed 
genes was combined to create a master list. From this master list, we refined the data set to 
identify genes unique to each study.  
 
Collaborators in the University of Pittsburgh Department of Biomedical Informatics performed 
Bioinformatic analysis.  
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Table 1. Data sets used for NextBio analysis. 
Set ID 
Number 
Cell Type Hormone Concentration Duration of 
Treatment 
Citation 
1 E14.5 cerebral 
cortex from Cav-1 
KO Mice 
Dexamethasone 0.1µM 4 hours This Study 
2 E14.5 cerebral 
cortex  from C57 
(Wild Type) mice 
Dexamethasone 0.1µM 4 hours This Study 
3 AtT-20 mouse 
pituitary 
Dexamethasone 0.1µM 4 hours (71) 
4 Multipotent human 
fetal hippocampal 
progenitor cell line 
(HPC03A/07) 
Cortisol 0.1µM 
 
12 hours (72) 
5 3134 mouse 
mammary 
adenocarcinoma 
Dexamethasone 0.1µM 
 
4 hours (71) 
6 C2C12 mouse 
myotubes 
Dexamethasone 1µM 24 hours (73) 
7 C2C12 mouse 
myotubes 
Dexamethasone 1µM 6 hours (73) 
8 Multipotent human 
fetal hippocampal 
progenitor cell line 
(HPC03A/07) 
Cortisol 100µM 12 hours (72) 
9 E14.5 cerebral 
cortex from rat 
Corticosterone 1µM 28 hours (30) 
10 Mouse 
oligodendrocyte 
precursor cell line 
(Oli-Neu) 
Dexamethasone 1µM 10 hours (74) 
11 Mouse 
oligodendrocyte 
precursor cell line 
(Oli-Neu) 
Dexamethasone 1µM 24 hours (74) 
12 Mouse 3T3-L1 
preadipocytes 
Dexamethasone 1µM 2 hours (75) 
13 Mouse 3T3-L1 
preadipocytes 
Dexamethasone 1µM 36 hours (75) 
14 Mouse C3H10T1/2 
pluripotent stem cell 
line 
Dexamethasone 1µM 1.5 hours (76) 
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Quantitative Real Time-PCR (qRT-PCR): For microarray validations, cells isolated from 
biologically independent samples of each genotype were treated with Dex or ethanol for 4 h and 
RNA processed using Machery-Nagel Nucelospin RNA II Kit. cDNA synthesis was performed 
using iScript Select cDNA Synthesis Kit (Bio Rad #170-8897). qRT-PCR reactions were 
performed on a Stratagene Mx3000P and used iTaq Universal SYBR Green Supermix (Bio Rad 
#172-5121) and primers with efficiencies calculated to be greater than 80%.  
 
Phospho-GR Westerns: Neurospheres from C57 or Cav-1 KO mice were treated with 100nM 
Dex for 1 h. Following treatment, cells were lysed in RIPA buffer (10mM Tris-Cl pH 8.0, 1 mM 
EDTA, 0.5 mM EGTA, 140 mM NaCl, 1% Triton-X, 0.1% Sodium Deoxycholate, 0.1% SDS) 
supplemented with 1:1000 HALT Protease and Phosphatase Inhibitors (Thermo #1861281). 
Lysate was subjected to immunoprecipitation using the BuGR2 mouse monoclonal antibody or 
incubated with non-immune IgG using standard laboratory conditions. Immunoprecipitated 
material was run on 7.5% SDS-PAGE gel and transferred to a PVDF membrane (Millipore 
Immobilon-P #IPVH00010). Western blot analysis was performed using the p211-GR antibody 
(17) and an anti-rabbit horseradish peroxidase secondary antibody (BioRad #170-6515) with a 
chemiluminescense detection system (Advansta Western Bright ECL #K-12045-D50).  
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 Nuclear Fractionation: Subcellular fractionation was performed according to guidelines 
provided in the NE-PER kit (Thermo #78833) with lysates from C57 or Cav-1 KO neurospheres 
treated with Dex or Ethanol for 4 h. Fractions were then separated on 10% SDS-PAGE gels and 
Western blots performed to detect total GR using the M20 rabbit polyclonal antibody (Santa 
Cruz, sc-1004) and Cav-1 (BD Biosciences #610059). The purity of fractions was assessed using 
GAPDH as a marker for cytoplasmic (Santa Cruz, sc-32233) and Lamin-B1 for nuclear proteins 
(Abcam, ab16048). 
 
Chromatin Immunoprecipitation (ChIP): NPSCs isolated from C57 or Cav-1 KO mice were 
grown as described above and treated with Dex or vehicle for 1.5 h. Cells were then fixed in 1% 
formaldehyde for 10 minutes at room temperature. Following fixation, 0.125 M glycine was 
added for 5 minutes to quench the cross-linking reaction. Cells were washed with PBS twice and 
frozen at -80 until immunoprecipitation. Prior to sonication, cell pellets were thawed on ice and 
lysed in ChIP Lysis Buffer (50mM HEPES, 1 mM EDTA, 140 mM NaCl, 10% Glycerol, 0.5% 
NP-40, 0.25% Triton X-100) with freshly added HALT Protease and Phosphatase Inhibitor 
Cocktail (Thermo-Fisher). Cell lysate was centrifuges at 5,000 RPM for 5 minutes at 4°C and 
crude nuclear pellets collected and washed once with ChIP Wash Buffer (10 mM Tris-Cl, 1 mM 
EDTA, 200 mM NaCl) with freshly added HALT Protease and Phosphatase Inhibitor Cocktail. 
The pellet was then resuspended in ChIP Sonication Buffer (10 mM Tris-Cl, 1 mM EDTA, 0.5 
mM EGTA, 0.5% N-lauroyl-sarcosine) with freshly added HALT Protease and Phosphatase 
Inhibitor Cocktail and chromatin sonicated using a Bioruptor into fragments of approximately 
500-1000 base pairs. Immunoprecipitation of GR was performed with 8 ug of a GR antibody 
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cocktail (2 ug each of M20 [Santa-Cruz], P20 [Santa-Cruz], H300 [Santa-Cruz] and BuGR2), 8 
ug phospho-serine 211 (ab55189), or normal Rabbit IgG (Santa-Cruz, sc-2027) overnight at 4°C. 
A 1:1 mix of anti-rabbit and anti-mouse Dynabeads (Life Technologies) were used according to 
manufacturer’s instructions. After incubation, beads were washed with low salt immune complex 
buffer (0.1% SDS, 1% Triton-X 100, 2 mM EDTA, 20 mM Tris-Cl pH 8.1, 150 mM NaCl), high 
salt immune complex buffer (0.1% SDS, 1% Triton-X 100, 2mM EDTA, 20mM Tris-Cl pH 8.1, 
500 mM NaCl), LiCl immune complex buffer (0.25 M LiCl, 1% NP-40, 1% deoxycholate, 1mM 
EDTA, 10mM Tris-Cl pH 8.1) and finally in 1x TE. Crosslinks were then removed via an 
overnight proteinase-K digestion (Ambion #AM2546) and DNA purified using a standard 
phenol-chloroform extraction protocol. Purified DNA was then analyzed using quantitative real-
time PCR. Primers were designed based on GR ChIP-Seq data published by (14, 15, 77, 78) and 
coordinates used are shown in Table 2.  
 
Table 2. Coordinates used to generate primers for ChIP analysis 
 
 
  
 
 
 
 
 
 
 
Gene Name Coordinates 
Fkbp-5 Chr17: 28556870-28557847 
RhoJ Chr12: 76404969-76405723 
Sgk-1 Chr10: 21683041-21683190 
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2.3 RESULTS 
2.3.1 Differences in the biology of Caveolin-1 Knock-Out and C57 Wild-Type CC-NPSCs. 
2.3.1.1 The Anti-Proliferative effects of Dex in CC-NPSCs Requires Cav-1 
The contribution of rapid GR signaling to the anti-proliferative effects of GCs exerted on a 
variety of tissue and cell types remains unresolved (36, 38, 56). Since rapid signaling effects of 
GCs on MAPK activation and GJIC are lost upon Cav-1 deletion in embryonic CC-NPSCs (29), 
we tested whether the anti-proliferative effects of GCs were altered in Cav-1 KO CC-NPSCs. As 
shown in Figure 5, Dex did not significantly impact proliferation of CC-NPSCs in Cav-1 KO 
neurospheres, which contrasts with C57 CC-NPSCs where proliferation was reduced by 10%. 
Furthermore, basal proliferation of embryonic CC-NPSCs was not affected by Cav-1 deletion 
(Figure 5A, 5B). Therefore, in embryonic CC-NPSC cultures, Cav-1 was an essential component 
of a GR signaling pathway that operates to limit proliferation. 
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 Figure 5. Anti-proliferative effects of Dex in CC-NPSCs requires Cav-1 
A. C57 or Cav-1 KO CC-NPSCs were treated with Dex or vehicle (Ethanol; EtOH) for 24 h and 
pulsed with BrdU during the last hour of treatment. Immunocytochemistry was performed to 
detect BrdU positive nuclei (pink). Nuclei were visualized by DAPI staining (blue). B. Three 
independent coverslips per biological replicate were counted to ascertain the percentage of cells 
that passed through S-phase (i.e. BrdU positive nuclei). Error bars represent SEM, n=3 biological 
replicates. One-way ANOVA with Tukey’s post test, p<0.001. 
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2.3.1.2 Cav-1 Deletion Abolished GR induction of Sgk-1, a Gene Required for the Anti-
Proliferative Effect of Dex in CC-NPSCs.  
We previously established that inhibition of GJIC by the rapid action of GR was associated with 
an inhibition of S-phase progression in cultured CC-NPSCs (29). Our observation that transient 
pharmacologic inhibition of GJIC is also sufficient to reduce CC-NPSC proliferation (29) was 
recently confirmed in cultured embryonic stem cell- derived neural progenitors and in embryonic 
neural progenitors isolated from the CC (79). Recent studies in human hippocampal neural 
progenitor cells indicate that the antiproliferative properties of GCs are dependent upon at least 
one genomic GR target gene, Sgk-1 (68). Consistent with these findings, Sgk-1 is also required 
for the anti-proliferative effect of GCs in our CC-NPSC cultures, since treatment with an SGK-1 
inhibitor (GSK650394) blunts the growth inhibitory affect of Dex (Figs. 6A, 6B). Sgk-1 was a 
GR target gene in C57 but not in Cav-1 KO CC-NPSCs as revealed by qRT-PCR analysis 
following a 4 hr Dex treatment (Fig. 6C). Thus, the role of Cav-1 in GC mediated effects on the 
cell cycle may extend beyond its impact on rapid GR signaling and influence genomic action of 
the receptor. 
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 Figure 6. Anti-proliferative effects of Dex in CC-NPSCs requires SGK-1 
A. C57 or Cav-1 KO cells were treated with Dex and/or the SGK-1 inhibitor, GSK650394 and 
the appropriate vehicle (EtOH or DMSO) for 24 h and pulsed with BrdU during the last hour of 
treatment. Immunocytochemistry was performed to detect BrdU positive nuclei (pink). Nuclei 
were visualized by DAPI staining (blue). B. Three independent coverslips per biological 
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replicate were counted to ascertain the percentage of cells that passed through S-phase (i.e. BrdU 
positive nuclei). Error bars represent SEM, n=3 biological replicates. One-way ANOVA with 
Tukey’s post-test, p<0.05. C. qRT-PCR analysis of Sgk-1 mRNA indicates that significant 
induction of Sgk-1 occurs after a 4 h Dex treatment in C57 but not Cav-1 KO CC-NPSCs 
(Student’s t-test, p<0.01). 
2.3.2 Cav-1 Deletion Results in Enhanced CC-NPSC Radial Migration 
Since both Cav-1 (61) and GC treatment (30) are implicated in altering cell migration, we next 
determined if loss of Cav-1 resulted in alterations in CC-NPSC migration. In the vehicle treated 
groups, loss of Cav-1 resulted in a significant increase in the total distance migrated (139.09 uM 
in C57 and 182.15 uM in Cav-1 KO) from the leading edge of the cell after 24 hours (Figure 7). 
Furthermore, in the Cav-1 KO cells, but not C57, Dex treatment resulted in significantly 
enhanced migration (Figure 7) (154.3 uM C57+ Dex and 139.09 uM C57 + EtOH versus 207.29 
uM Cav-1 KO + Dex and 182.16 uM Cav-1 KO +EtOH).  Therefore, loss of Cav-1 results in 
enhancement of CC-NPSC radial migration. 
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 Figure 7. Loss of Cav-1 results in Enhanced CC-NPSC migration. 
 
Neurospheres were allowed to adhere to PDL treated tissue 6-well tissue culture dishes and 
migrate in the presence of Dex or EtOH over a period of 24 hours. Approximately 30 spheres per 
condition per replicate were analyzed using ImageJ to ascertain the total distance migrated. 
Under basal conditions, Cav-1 KO CC-NPSCs migrate further than corresponding C57 CC-
NPSCs. Cav-1 KO, but not C57 CC-NPSCs also have a pro-migratory response to Dex 
treatment.  n=4 C57 and n=4 Cav-1 KO, One-way ANOVA with Tukey’s post test, * indicates 
p<0.05. 
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2.3.3 Cav-1 Deletion Alters GC-Induced Differentiation of Oligodendrocytes 
Previous studies revealed a role for Cav-1 in regulating astroglial and neuronal differentiation 
(64, 65). Recent work in the adult rat hippocampus revealed that stress or exogenous treatment 
with GCs results in decreased neurogenesis and enhanced oligodendrogenesis (31). Therefore, 
we used an in vitro differentiation assay to determine if loss of Cav-1 or treatment with Dex 
resulted in changes in the abundance of oligodendrocyte progenitors. Preliminary data indicates 
that at P1 and P3, in both C57 and Cav-1 KO cells, treatment with Dex results in an increase in 
the abundance of olig2 positive cells. Olig2 is a marker for oligodendrocyte progenitors therefore 
this data suggests that the differentiation of oligodendrocytes is enhanced in response to Dex 
treatment (Figure 8, Table 3). Interestingly, in P1 Cav-1 KO CC-NPSCs there appears to be a 
stronger Dex effect at P1 that is lost by P3, whereas in C57 CC-NPSCs, the greatest Dex 
response is observed at P3 (Table 3) indicating that sensitive periods where oligodendrocyte 
differentiation can be influenced by Dex varies in response to loss of Cav-1.  
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Figure 8. Preliminary data indicates that loss of Cav-1 results in altered GC-induced differentiation 
of oligodendrocytes.  
P3 neurospheres from C57 or Cav-1 KO animals were treated for 24 hours with Dex or EtOH, 
dissociated, and plated on PDL and laminin treated coverslips in the presence of differentiation 
media and no growth factors. Cells were allowed to differentiate for a period of 24 hours prior to 
fixation and processing for immunocytochemistry.   The number of olig2 (pink) positive cells 
was ascertained on independent coverslips to obtain the average percentages shown in Table 1. 
n=1 C57 and n=1 Cav-1 KO. Nestin, a marker of neural stem cells is shown in green.  
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Table 3. Percentage of olig2 labeled cells in P1 and P3 CC-NPSCs at 1DD. 
Olig2 Positive Cells P1 P3 
C57 + EtOH 56.7% 49.08% 
C57 + Dex 62.7% 73.8% 
Cav-1 KO + EtOH 60.8% 61.6% 
Cav-1 KO + Dex 79.75% 72.4% 
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2.4 ALTERATIONS IN GR MEDIATED GENE EXPRESSION BETWEEN CAV-1 
KO AND C57 CC-NPSCS 
2.4.1 Analysis of Cav-1 loss on GR Transcriptome in CC-NPSCs. 
To examine Cav-1 regulation of genome-wide GR transcriptional responses, C57 and Cav-1 KO 
CC-NPSCs were subjected to microarray expression analysis. When compared to C57 CC-
NPSCs, Cav-1 KO cells demonstrate differential basal expression of 186 genes (FDR < 0.1) with 
44 genes exhibiting higher expression in Cav-1 KO cells and 20 genes lower expression by at 
least 1.5 fold. The transcripts with lowest expression in the Cav-1 KO versus C57 cells were 
Cav-1, as expected, and the ribosomal protein S9 (Rps9) gene, whose expression had previously 
been shown to be highly dependent upon Cav-1 (80). When Dex treated Cav-1 KO and C57 CC-
NPSCs were compared for gene expression, 568 genes (excluding Cav-1 and Rps9) were 
differentially Dex responsive (FDR < 0.1). In general, Dex responsive genes were regulated in 
the same direction in both C57 and Cav-1 KO CC-NPSCs as shown in a heat map (Figure 9). 
However, individual genes do exhibit differences in Dex responsiveness between the two 
genotypes.  
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Figure 9. Loss of Cav-1 results in differential regulation of a subset of GR target genes. 
 
Dex responsive genes between C57 and Cav-1 KO CC-NPSCs were clustered using Pearson’s 
dissimilarity as distance measure and Average Linkage method for linkage analysis. The data are 
represented using a z-score normalized before plotting the heatmap. For each gene (row), the Z-
score is calculated by subtracting the expression value by mean expression across all samples 
(centering) and dividing by standard deviation (scaling). 
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A number of genes that were induced by Dex at least 2.5 fold and exhibited robust 
differences in Dex regulated expression between C57 and Cav-1 KO CC-NPSCs were validated 
by qRT-PCR using independent NPSC cultures  (Figure 10). For this analysis, we examined both 
well-established GR target genes (e.g. Fkbp-5) and genes with limited reports of GC 
responsiveness (e.g. Gcnt2).  Specifically, Dex induction of Fkbp-5, Gcnt2, RhoJ, Pcolce2, Mal, 
Adm and Arl4d mRNA expression was significantly reduced in Cav-1 KO versus C57 CC-
NPSCs (Figure 10). We also observed that Cxcr4 did not attain similar levels of repression in 
response to Dex treatment in Cav-1 KO CC-NPSCs (Figure 10). Therefore, Cav-1 effects on GR 
action are not limited to rapid signaling (29) but also extend globally to genomic responses.  
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 Figure 10. A subset of genes is differentially regulated by GR in C57 versus Cav-1 KO CC-NPSCs. 
C57 or Cav-1 KO NPSCs from tissues independent of those used for microarray analysis were 
treated for 4 h with 100 nM Dex and mRNA expression of indicated genes analyzed using qRT-
PCR. Although all genes shown are significantly induced in response to Dex, activation is 
attenuated in the Cav-1 KO cells. Error bars represent SEM, n=6. Student’s t-test, * represents 
p<0.05, ** represents p<0.01. 
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Ingenuity® pathway analysis (IPA) was used to examine components of molecular 
networks and pathways defined by Dex regulated genes in C57 and Cav-1 KO CC-NPSCs. As 
shown in Figure 11C and 11D, the most significant functional networks defined by Dex 
responsive genes in C57 CC-NPSCs were distinct from networks formed in Cav-1 KO CC-
NPSCs. For example, in C57 CC-NPSCs, cell cycle genes comprise the top two highly rated 
networks; 9 of the next 10 highly rated gene networks included molecules involved in 
development, particularly in the nervous system (Fig. 11C). Figure 4A shows the most highly 
rated cell cycle network in Dex treated C57 NPSCs. Included in this network are genes such as 
Pcolce2 (Fig. 10C) and Zbtb16 (data not shown), which were validated as GR targets by qRT-
PCR of independent samples. In addition, top canonical pathways within this cell cycle network 
include a number of nuclear receptors; retinoid acid receptor, GR, peroxisome proliferation 
activating receptor alpha (PPARa)/retinoid X receptor alpha (RXRa), estrogen receptor and 
thyroid hormone receptor/RXRa. 
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Figure 11. Dex regulated genes in C57 and Cav-1 KO CC-NPSCs comprise distinct cell cycle 
regulated networks. 
IPA analysis using lists from Dex regulated genes in C57 (A, C) and Cav-1 KO (B,D) CC-
NPSCs define distinct cell cycle networks shown. Upregulated genes are depicted in red and 
downregulated genes in green. The shading of red and green symbols indicates the extent of Dex 
upregulation or downregulation, respectively.  
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In contrast to C57 Dex regulated networks, Cav-1 KO CC-NPSCs demonstrated only one 
highly rated network involved in nervous system development (Fig. 11D). Although GR 
signaling pathways were part of nervous system development networks in both Dex treated C57 
and Cav-1 KO CC-NPSCs, the genes in the two networks were different (Fig. 12A, 12B). In 
addition, the only cell cycle network (6th highest) in Dex regulated Cav-1 KO CC-NPSCs was 
unrelated to the highest rated cell cycle network in Dex treated C57 CC-NPSCs (Figs. 11A, 
11B).  
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Figure 12. Dex regulated genes in C57 and Cav-1 KO CC-NPSCs comprise distinct nervous system 
development networks. 
IPA analysis using lists from Dex regulated genes in C57 (A) and Cav-1 KO (B) CC-NPSCs 
define distinct nervous system development networks shown. Upregulated genes are depicted in 
red and downregulated genes in green. The shading of red and green symbols indicates the extent 
of Dex upregulation or downregulation, respectively.  
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The previous analysis used Dex regulated genes from C57 and Cav-1 KO CC-NPSCs, 
including those that were similarly responsive to hormone in the two genotypes.  To examine 
differences in Dex responsiveness between the two genotypes, IPA analysis was performed using 
genes determined to be significantly different by ANOVA with regards to Dex response. This 
analysis showed that approximately half (i.e. 13) of the 25 highly rated networks formed by 
differentially Dex responsive genes were involved in some aspect of organ or tissue development 
(Figure 13C). In fact, the most highly rated networks function in nervous system development 
(Figure 12A, 12B), protein ubiquitylation (Figure 13C), and axon guidance or 
cellular/extracellular matrix interactions (Figure 13C). GC effects on neuronal migration and 
ubiquitin-proteasome mediated degradation have previously been observed in neural stem cells 
(36, 81) and may be influenced by Cav-1. 
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Figure 13. Genes differentially regulated by Dex in C57 versus Cav-1 KO CC-NPSCs comprise distinct 
nervous system development networks. 
Shown are the top two distinct nervous system development networks defined by IPA analysis 
using lists from genes differentially regulated by Dex in C57 (A) versus Cav-1 KO (B) CC-
NPSCs. Upregulated genes are depicted in red and downregulated genes in green. The shading of 
red and green symbols indicates the extent of Dex upregulation or downregulation, respectively. 
Panel C indicates the 25 most highly rated networks formed by genes differentially responsive to 
Dex. 
 
To summarize, in addition to identification many novel primary GC responsive genes in 
CC-NPSCs, our microarray data implicated Cav-1 as a modulator of both rapid signaling and 
genomic action of GR. 
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2.4.2 Identification of Novel Dex Regulated Genes in CC-NPSCs. 
To identify Dex regulated genes that are unique to neural stem cells, the NextBio® data mining 
tools (see Methods) were used to compare the GR regulated transcriptome in CC-NPSCs to 
others from cell and tissue sources as diverse as the 3134 mouse mammary adenocarcinoma cell 
line (71) and a mouse oligodendrocyte progenitor cell line (74) (Table 1). Specifically, this 
analysis included 14 separate studies; a union of differentially expressed genes from each of 
these studies generated 5000 GC regulated genes. A comparison of the GC regulated gene list in 
our NPSC cultures (Fig. 14A, Set 3) with a subset of these studies that used closely related cell 
types (i.e. rat neural (30) and oligodendrocyte progenitors (74); Fig 14A, Set 2) revealed 176 
common genes (Fig. 14A). However, of the 5000 GC regulated genes from 14 data sets only 6 
were uniquely GC regulated in our mouse NPSC cultures--Gjb6, Gbx2, Card10, Plcl2, Smc5, 
Rnf157. Three of these genes (Gjb6, Gbx2, Plcl2) were validated as Dex regulated in qRT-PCR 
analysis of independent samples (Figs. 14B-D). Therefore, the GR transcriptome in three-
dimensional cultures of mouse NPSCs only included a limited number of unique target genes.  
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 Figure 14. Next-Bio analysis reveals a subset of genes regulated by Dex in embryonic mouse CC-NPSC 
cultures. 
A. Venn diagram comparing the GC-regulated gene lists in the 14 studies used to perform meta-
analysis in NextBio. The genes contained in Set 1 are from study ID# 3-8, 12-14 (Table 1) and 
derived from cell types most distant from our mouse embryonic CC-NPSCs (Set 3). The genes 
contained in Set 2 are from study ID# 9-11 (Table 1) and derived from cell types closely related 
to our mouse embryonic CC-NPSCs (i.e. rat neural progenitors or mouse oligodendrocyte 
progenitor cells). B-D. C57 KO CC-NPSCs from tissues independent of those used in the 
microarray were treated for 4 h with 100 nM Dex and induction of Gjb6 (B), Plcl2 (C) and Gbx2 
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(D) mRNA analyzed using qRT-PCR. Error bars represent SEM, n=6. Student’s t-test, * 
represents p<0.05, *** represents p<0.001. 
 
One of the most highly induced genes uncovered in our microarray dataset was the cystic 
fibrosis transmembrane regulator (CFTR). CFTR is a chloride ion channel implicated in cystic 
fibrosis and is also expressed in neurons where it works with NKCC1 to regulate synaptic events 
(82). Using biological materials from samples independent of those used for the microarray 
analysis, the induction of CFTR in CC-NPSCs was validated (Figure 15A). To assess if a 
previous exposure to glucocorticoids, either the synthetic Dex or the natural ligand 
Corticosterone or Cort, resulted in long lasting effects on later expression of Cftr, we performed 
a “memory” experiment where cells were treated at P1 with GC, cultured under naïve conditions 
for an additional two weeks, and then re-treated for four hours (See §3.2, Figure 22) . Both Dex 
and Cort treatment results in reduced induction of Cftr at P3, indicating that a previous hormone 
exposure can influence later GC-regulated transcriptional activity.  
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 Figure 15. CFTR is a novel GR regulated gene in CC-NPSCs. 
A. After four hours of Dex treatment, the mRNA expression of Cftr is substantially induced  
(n=6, Student’s t-test, p<0.05). B. Pre-exposure of CC-NPSCs to Dex for one hour at P1 and 
subsequent analysis at P3 after treatment with Dex or cortisol (Cort) indicates that previous 
exposure to Dex influences later GR-mediated expression of Cftr (n=3, One-way ANOVA with 
Tukey’s Post Test, * indicates p<0.05).   
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2.5 MECHANISMS FOR ALTERATIONS OF GR REGULATED GENE 
EXPRESSION IN CAV-1 KO CC-NPSCS  
2.5.1 Cav-1 protein is not detectable in the nucleus of CC-NPSCs, nor does loss of Cav-1 
impact mRNA or protein expression of GR 
To determine a mechanism for Cav-1 effects on GR transcriptional activity, we first sought to 
determine if Cav-1 was found in the nucleus of CC-NPSCs. In ovarian carcinoma cell lines, Cav-
1 regulates cell cycle regulatory gene expression through direct DNA binding (83). Cav-1 also 
affects transcription in lung epithelial Beas-2B cells by directly binding the transcription factor 
nuclear erythroid 2 p45-related factor 2 (Nrf2) (84). Our previous work (29) revealed an 
interaction between Cav-1 and GR in CC-NPSCs. However, Cav-1 was undetectable in nuclear 
fractions prepared from untreated or Dex-treated CC-NPSCs (Fig. 16). Dex-dependent nuclear 
translocation of GR occurred in both genotypes (Fig. 16).  
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 Figure 16. Fraction experiments indicate no detectable Cav-1 protein in the nucleus. 
Cytoplasmic and nuclear fractions prepared from C57 and Cav-1 KO CC-NPSCs treated for 1 h 
with 100 nM Dex or EtOH vehicle were subjected to Western Blot analysis to detect GR, Cav-1 
and markers for cytoplasmic (GAPDH) or nuclear (Lamin-B1) proteins. Cav-1 was not detected 
in nuclear fractions from C57 CC-NPSCs lysates and in either cytoplasmic or nuclear fractions 
from Cav-1 KO cells. Blot shown is representative of three independent experiments.  
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Furthermore, GR protein and mRNA levels were unaltered in Cav-1 KO CC-NPSCs 
(Figure 17). Therefore, Cav-1 may indirectly affect GR transcriptional response via regulation of 
a cytoplasmic signaling pathway that ultimately impacts GR bound at specific gene targets. 
 
Figure 17. Loss of Cav-1 does not impact mRNA or protein expression of the GR in CC-NPSCs 
A. qRT-PCR analysis indicated no difference in GR mRNA expression between C57 and Cav-1 
KO cells (n=5). B-C Western Blot analysis also indicated no difference in GR protein (relative to 
GAPDH) expression between C57 and Cav-1 KO cells treated with 100 nM Dex or EtOH 
vehicle for 4 h (n=4) Error bars represent SEM. 
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2.5.2 Cav-1 Influences Site Specific GR Phosphorylation 
Site-specific GR phosphorylation influences its transcriptional regulatory activity. In fact, 
different phosphorylation patterns within the amino-terminal activation function-1 domain can 
dictate which target genes will be bound by GR (17). Both MAPKs, targets of rapid GR 
signaling, and cyclin dependent kinase-2 (CDK2), phosphorylate GR and influence its 
transcriptional activity (18). Therefore, we tested the impact of Cav-1 deletion on MAPK and 
CDK2 dependent phosphorylation of GR at Serine 211 (S211) and Serine 226 (S226), 
respectively. As shown in Figure 18, phosphorylation at S211, a Dex responsive site, was 
undetectable in Cav-1 KO neurospheres. Since hormone-dependent phosphorylation at S211 is 
associated with transcriptionally active GR, the loss of phosphorylation at S211 may explain 
diminished Dex responsiveness of select genes in Cav-1 KO CC-NPSCs (e.g. Figure 10). GR 
phosphorylation at S226 is unaltered in Cav-1 KO CC-NPSCs. Therefore, Cav-1 does not alter 
global GR phosphorylation.  
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 Figure 18. GR phosphorylation at S211, but not S226 is altered in Cav-1 KO CC-NPSCs. 
Whole cell lysates from C57 and Cav-1 KO NPSCs treated for 1 h with 100 nM Dex or EtOH 
vehicle were subjected to immunoprecipitation with the BuGR-2 mouse monoclonal antibody 
against GR or non-immune mouse IgG and then subjected to Western blot analysis to detect total 
GR, phospho-S211 or phospho-S226 GR isoforms. Asterisk shows non-specific band detected in 
all lanes following pull-down with non-immune IgG. The identity of the higher molecular weight 
band in the input lane (star) is unknown but it is not detected in anti-GR antibody 
immunoprecipitates. The Dex inducible phospho-S211 isoform, detectable in C57 but not Cav-1 
KO CC-NPSC lysates, is indicated by the arrow. GR phosphorylation at S226 is similar in C57 
and Cav-1 KO lysates. Blot is representative of three biologically independent experiments. 
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2.5.3 Cav-1 Influences Recruitment of GR to Target Genes 
We next determined if any of the genes differentially regulated in C57 and Cav-1 KO CC-
NPSCs (Figure 10) were direct targets of GR and if recruitment of GR to gene regulatory regions 
was altered in Cav-1 KO cells. Directed chromatin immunoprecipitation (ChIP) assays were used 
to reveal GR recruitment to select target genes affected by Cav-1 KO, using previously reported 
GR binding sites in other cell lines (14, 15, 77, 78). As shown in Figure 19, three genes validated 
as differentially expressed in C57 versus Cav-1 KO CC-NPSCs have significantly decreased 
chromatin recruitment of GR in response to Dex treatment in Cav-1 KO CC-NPSCs (Figure 
19A-C). Since GR phosphorylation at Ser211 is undetectable in Cav-1 KO cells (Figure 18) we 
did not expect to detect any recruitment of pSer211-GR to glucocorticoid regulated genes. 
Nonetheless, this we confirmed by ChIP assays with the pSer211-GR antibody as shown in 
Figure 19D, which also demonstrated diminished recruitment of pSer211-GR to the Sgk-1 
promoter in C57 CC-NPSCs. Therefore, reduced transcriptional responses to Dex in Cav-1 KO 
CC-NPSCs can be mediated by diminished recruitment of select GR phosphoisoforms to target 
gene regulatory sites.  
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 Figure 19. Chromatin immunoprecipitation experiments indicate altered recruitment of total and pSer-211 
GR. 
Chromatin Immunoprecipitation experiments using total GR (B-D) or phospho-S211 (E) 
antibodies indicates attenuated recruitment of GR to target genes in response to a 1.5 h treatment 
with 100 nM Dex. DNA was analyzed via qRT-PCR and final values shown are relative to total 
and IgG negative control before comparing enrichment in Dex vs. EtOH (n=3 biological 
replicates for C57 and n=5 for Cav-1 KO cells). Error bars represent SEM, Student’s T-test, * 
represents p<0.05 and ** p<0.01. 
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2.6 DISCUSSION 
The non-classical rapid activation of nuclear receptors residing at the plasma membrane 
mobilizes various cytoplasmic signaling pathways that can either directly alter cellular 
physiology (29, 56) or indirectly modulate transcriptional responses (58). Such crosstalk between 
rapid nuclear receptor signaling and classical genomic action can utilize nuclear receptors at 
target genes or independent transcription factors. In this report, we demonstrated that crosstalk 
between GR rapid and genomic pathways in embryonic NPSCs utilized Cav-1, a lipid raft 
protein.  Cav-1 did not act as a classical coregulator of GR on genomic targets but rather altered 
the phosphorylation of GR on at least one site, S211. Phosphorylation of S211 in U2OS cells 
influences the GC transcriptional program (See §1.1) (17), and may likewise impact target genes 
regulated by GR in CC-NPSCs. In fact, alterations of the GR transcriptome in CC-NPSCs upon 
Cav-1 deletion define unique networks that potentially alter GC regulation of the cell cycle (See 
Model, Figure 20).  
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 Figure 20. Model for Cav-1 mediated effects on genomic action of GR.  
As shown on the right hand side of the figure, previous work demonstrated that GR binds to the 
promoter of Sgk-1 (85), a GR target implicated in the anti-proliferative effects of GC in neural 
progenitor cells (68). New findings presented in this chapter are surrounded by red rectangles.   
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2.6.1 Loss of Cav-1 Results in Alterations in the GR Transcriptome in CC-NPSCs 
The most prominent pathways defined by the GR transcriptome in C57 CC-NPSCs involved cell 
cycle progression and contain a number of genes that could contribute to the anti-proliferative 
effects of GCs (29, 36, 56). Notably, one validated GR target gene, Sgk-1, is required for the 
anti-proliferative effects of GC in embryonic mouse CC-NPSCs (this report) and a human 
hippocampal progenitor cell line (68) but did not reach significance as GC regulated in our 
microarray analysis or in analysis of hippocampal progenitors (72). The high stringency applied 
to microarray data sets, while reducing the number of false positives, may miss bona fide GR 
targets that play an important role in the biological effects of GCs. The inability of GR to induce 
Sgk-1 expression in Cav-1 KO CC-NPSCs may underlie in part the loss of an antiproliferative 
response to Dex. However, it may be possible that the lack of anti-proliferative response in the 
Cav-1 KO may be due to fundamental differences in basal proliferation resulting in a state where 
the rate of cell cycling cannot be attenuate further. Importantly, a number of cell cycle regulated 
genes were also found to be differentially responsive to Dex in C57 versus Cav-1 KO CC-
NPSCs so there are likely to be multiple GR targets that participate in the complex regulation of 
proliferation in CC-NPSCs, which are influenced by Cav-1. Since the GR transcriptome in C57 
and Cav-1 KO embryonic CC-NPSC cultures also defines a number of pathways implicated in 
neuronal development, future studies may reveal a role for Cav-1 operating through either rapid 
signaling (29) or crosstalk with genomic GR pathways to influence antenatal effects of GCs on 
neurodevelopment.  
Our study supports a role for Cav-1 in mediating genomic action of GR in addition to its 
role in rapid GR signaling. CC-NPSCs null for Cav-1 contain a subset of genes that are 
differentially regulated by GR in response to Dex. All of the genes validated exhibited no 
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differences in basal expression, except for Pcolce2, which demonstrated slight variability, but 
not enough to offset the difference in Dex induced expression. Of the subset that we validated, 
Fkbp5 is a known target of GR involved in negative regulation of GR and the stress response. 
Improper regulation and expression of Fkbp5 can contribute to neuropsychiatric diseases such as 
post-traumatic stress disorder (see §. 3.1.1). Alterations in regulation of Fkbp5 may explain why 
adult Cav-1 KO animals tend to exhibit more anxious behaviors than their wild type counterparts 
(66). Additional studies in Cav-1 KO animals assessing cortisol reactivity and FKBP5 levels 
after exposure to a stressor may indicate changes in the HPA axis, which may underlie the 
anxious behaviors.  
2.6.2 Identification of Novel GR Target Genes in CC-NPSCs 
Gjb6, Gbx2 and Plcl2 were novel validated GR target genes in CC-NPSC cultures but their role 
in regulating neural stem or progenitor cell function has yet to be determined. Gjb6 encodes 
connexin 30, a gap junction protein expressed primarily in astrocytes but not until postnatal day 
10 in mice (86). Therefore, Dex induction of Gjb6 in our neurosphere cultures may be reflective 
of GR action in astrocyte progenitor cells. Future experiments utilizing specifically astrocyte 
progenitor cells either isolated by fluorescence activated cell sorting or identified using 
immunocytochemistry treated with Dex could indicate if Gjb6 expression is specific to this 
population of cells. Gbx2 is a homeobox transcriptional factor that has been shown to regulate 
various aspects of neural stem cell differentiation (87) and may contribute to reported effects of 
GCs on differentiation of distinct neuroprogenitors (38-40). Preliminary data indicates that the 
differentiation of oligodendrocyte progenitors may be altered in the Cav-1 KO CC-NPSCs. Data 
from others (31) and preliminary evidence from our lab indicates that Dex treatment in wild type 
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cells yields increased differentiation of oligodendrocytes with the largest effect seen in P3 CC-
NPSCs. In the Cav-1 KO, it appears that the largest increase in the number of oligodendrocyte 
progenitors post Dex treatment occurs at P1. Since CC-NPSCs are able to recapitulate in vivo 
differentiation in vitro, the enhanced respond to Dex treatment at P1 in the Cav-1 KO versus P3 
in C57 may indicate the existence of “sensitive” periods during development where cells are 
particularly susceptible to GC induced changes. In the Cav-1 KO, this GC-sensitive period may 
occur earlier possibly due to changes in gene expression. Future experiments addressing 
alterations in response to GC treatment in vivo in Cav-1 KO versus C57 animals may indicate 
further abnormalities in oligodendrocyte differentiation and maturation.  
No role for phospholipase C-related protein (Plcl2) in neurodevelopment or GC 
action has been reported although Plcl2 was identified in exome sequencing analysis as 
one of 40 genes with protein coding sequence variations in Schizophrenia patients (88). Notably, 
prenatal stress is thought to contribute to the development of schizophrenia (54). Our analysis 
revealed that one of the most highly regulated genes in our dataset was Cftr. Cftr is expressed 
throughout the human brain (89) and in embryonic but not adult rabbit brain (90). Further 
analysis of publically available DNA Hypersensitivity Assay datasets indicated an area of open 
chromatin around Cftr present only in E14.5 and E18.5 mouse brain tissue and not adult brain 
tissues (See Appendix 1, Figure 30). Previous work in a porcine model demonstrated that CFTR 
is functional within Schwann Cells. New born pigs null for Cftr demonstrate alterations in 
myelin sheath, reduced axonal density, and decreased nerve conduction velocity, therefore 
supporting a role for Cftr in the developing nervous system (91). We also observed that 
transcription of Cftr can be permanently altered in response to an earlier GC treatment, and 
without fully understanding the role of Cftr in cerebral cortex development, the full implications 
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of this altered regulation are unknown. Furthermore, microarray studies in oligodendrocyte 
progenitor cell lines indicate that in cells stimulated to differentiate in the presence of Dex, 
expression of Cftr is induced (74). Therefore, these data may indicate an role for Cftr in the 
developing brain, and another method by which GC treatment could alter later neuronal function.    
2.6.3 Top Differentially Regulated Genes Between C57 and Cav-1 KO CC-NPSCs are 
Involved in Nervous System Development 
Of the 25 highly rated networks identified by our analysis of genes differentially responsive to 
Dex in C57 versus Cav-1 KO CC-NPSCs, approximately half were related to organ or tissue 
development—the top two from our dataset involving nervous system development. Notably, 
one of these pathways involves protein ubiquitinylation. Multiple studies have revealed an 
impact of GCs on protein degradation of NPSCs. For example, GC treatment in rat embryonic 
neural stem cells results in decreased proliferation by enhancing ubiquitin-mediated degradation 
of the cell cycle regulator, Cyclin-D1 (36). In embryonic rat cells, Dex treatment increases 
expression of a deubiquitinating enzyme, Usp8/Ubpy that can indirectly cause increased 
degradation of the BRUCE/Apollo inhibitor of apoptosis protein. As a result of increased 
BRUCE degradation, there is a consequent decrease in cell proliferation (81). Interestingly, Cav-
1 interacts with and regulates the polyubiquitinylation of active Rac1 (92). Rac1 is a member of 
the Rho-like GTPases and also involved in actin polymerization and protrusion and cell 
migration. Therefore, loss of Cav-1 may influence cell migration in NPSCs mediated by Rho-
like GTPases. 
The second most highly regulated pathway we uncovered during our network analysis 
involved axon guidance. Interestingly, RhoJ, and Arl4D were validated as genes differentially 
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regulated between C57 and Cav-1 KO and are both implicated in actin mediated cell migration 
(93, 94). Furthermore, Cxcr4 was also validated as a differentially regulated gene and is 
implicated in dopaminergic cell migration (95). GC effects on neural stem cell migration are well 
documented (30). Therefore, GR signaling mediated by Cav-1 could have a critical impact on the 
biology and development of CC-NPSCs by regulating the degradation of cell cycle regulators or 
migration of differentiated cells derived from CC-NPSCs to their final position in the cortex. 
Radial migration assays indicated that Cav-1-KO CC-NPSCs are more pro-migratory than their 
C57 counterparts—a phenomenon that is enhanced upon treatment with Dex. Since RhoJ and 
Arl4D are pro-migratory and Cxcr4 is anti-migratory, and all three do not reach the same levels 
as C57 of activation/repression in the Cav-1-KO, this indicates that there may be other genes or 
mechanisms that are dysregulated upon loss of Cav-1 to result in enhanced migration, and 
treatment with Dex results in a synergistic effect.  
2.6.4 Changes in GR Transcriptome Linked to Alterations in Phosphorylation of GR at 
S211 
Although Cav-1 was not found in the nucleus of CC-NPSCs, it influenced site-specific GR 
phosphorylation, which in turn could impact the GR transcriptome. Specifically, phosphorylation 
at S211, but not S226, was affected in Cav-1 KO CC-NPSCs. Therefore, the GC response of 
genes that require pSer211-GR to reach peak activation may be altered in Cav-1 KO CC-NPSCs. 
For example, pSer211-GR is recruited to promoters of genes such as Gilz and Tat to activate 
their transcription (17). Since GR phosphorylated at S211 is associated with activated gene 
transcription, alterations in pSer211-GR are consistent with the attenuated activation of select 
GR target genes in Cav-1 KO CC-NPSCs. Results from ChIP assays on select GR target genes 
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provide additional mechanistic insights regarding the role of Cav-1 in GC regulated transcription 
and show reduced recruitment of GR (and pSer211-GR) to select regulatory regions of genes 
differentially responsive to Dex in C57 versus Cav-1 KO CC-NPSCs. Since GR is recruited to 
multiple binding sites of its target genes, a more comprehensive analysis of the GR cistrome in 
C57 versus Cav-1 KO CC-NPSCs using ChIP-seq will be required to uncover other mechanistic 
features of site-specific Cav-1-dependent GR recruitment. Given that the majority of Dex 
regulated genes in CC-NPSCs were unaffected by Cav-1 KO, GR chromatin recruitment is not 
globally regulated by Cav-1. Finally, other future experiments directed towards identifying genes 
occupied by distinct GR phosphoisoforms (e.g. pSer211-GR) in CC-NPSCs could identify 
specific GC regulated gene networks that are influenced by crosstalk with cytoplasmic signaling 
pathways. In fact, alterations in GR phosphorylation in specific adult rat brain regions are 
generated in response to specific stresses and may impact select genes that modulate behavioral 
responses to stressful states (96). 
Phosphorylation of GR at S211 and S226 is mediated by two different kinases—CDK2 at 
S211 and MAPK at S226. Others have suggested that Cav-1 is a tumor suppressor gene due to its 
role in mitogenic signaling (97). Ablation of Cav-1 in metastatic lung cancer cell lines results in 
proliferation arrest and decreased expression of cyclin-D1 and CDK4 (97). Therefore, Cav-1 loss 
may independently affect the expression or activity of cell cycle regulators or in conjunction with 
rapid GR signaling impact CDK2 and consequently genomic action of GR. 
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2.6.5 Summary 
In summary, Cav-1 is a multi-functional regulator of GR action in NPSCs. Cav-1 influences both 
GR-dependent rapid changes in intercellular communication through gap junctions (29), which is 
required for establishment of cerebral cortical architecture (79) and the GR transcriptome, 
including genes responsible for regulating NPSC proliferation. The wide variety of GR gene 
networks affected by Cav-1 also suggests that this novel regulator of receptor action could 
impact the ultimate fate and laminar position of cells derived from embryonic cerebral cortical 
NPSCs exposed prematurely to GCs during fetal development. 
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3.0  GLUCOCORTICOID TREATMENT OF HYPOTHALAMIC NPSCS RESULTS 
IN SEXUALLY DIMORPHIC AND LONG LASTING CHANGES IN REGULATION OF 
GR TARGET GENES  
3.1 INTRODUCTION 
3.1.1 The Hypothalamus Links the Central Nervous and Endocrine Systems 
During embryonic development, the hypothalamus (HT) derives from a region of the ventral 
diencephalon known as the hypothalamic sulcus that can be distinguished morphologically from 
embryonic day 9.5 in the mouse (98, 99). Proper patterning of the HT involves the contribution 
of several signaling pathways including sonic hedgehog and Wnt signaling (reviewed in (99)). 
Several transcription factors serve important roles in proper development of the HT. For 
example, without SIM1 and/or its dimerization partner ARNT2, mutant mice are lacking all 
neurons that comprise the paraventricular nucleus (99). SIM1 and ARNT2 also control the 
regulation of Brn2, another transcription factor with an essential role in the differentiation of 
corticotropin releasing hormone (CRH) neurons (99). SF1 is a member of the NR superfamily 
and knock-out studies indicate an essential role for SF1 in mediating survival, migration, and 
differentiation within the hypothalamus (99).  
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 Although the HT serves as a link between the central nervous and endocrine systems, it 
compromises a very small percentage of the overall brain volume, slightly less than 2% (100). 
The mature hypothalamus is located beneath the thalamus and adjacent to the pituitary gland. 
The HT can be classified into three distinct regions: the periventricular, medial and lateral. Each 
of these three regions contain specific nuclei or regions  such as the paraventricular nucleus and 
anterior hypothalamus each having specific functions and controlling a wide variety of processes 
including growth, metabolism and reproduction (99). Distributed throughout the HT are a variety 
of neurosecretory neurons. These include cells that secrete CRH, an important component of the 
hypothalamic-pituitary adrenal (HPA) axis, and cells that secrete thyrotropin-releasing hormone 
to regulate the production and release of thyroid hormone (reviewed in (99)). The secretion of 
CRH (and others) then stimulate the anterior pituitary to control hormone secretion (99). 
 One of the critical roles of the HT is in regulation of the HPA axis, a physiological 
process that contributes to regulation of the body’s stress response (Figure 21). In response to 
stress or as a part of normal circadian rhythms, the hypothalamus secretes CRH. CRH then 
stimulates the transcription of pro-opiomelanocortin (POMC) within the pituitary gland, which 
then gives rise to adrenocorticotropic hormone or ACTH. ACTH travels through the blood 
stream to the adrenal cortex, a heavily vascularized gland residing above the kidneys. The 
adrenal gland is comprised of three areas, each of which gives rise to a different hormone in 
response to signals from the pituitary gland. In the case of the HPA axis, ACTH stimulation 
leads to the production of GCs from the region of the adrenal gland known as the zona 
fasciculate. These GCs act in a variety of manners through the GR in all cell types of body to aid 
in the body’s response to a stressful situation. GCs are integral in shutting down the stress 
response at all levels. For example, GCs decrease the transcription of POMC, which then leads to 
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less production of ACTH. Furthermore, GCs also inhibit the production and secretion of CRH. 
At the level of the GR, GC stimulation causes increased transcription of Fkbp5, leading to 
increased levels of FK506 binding protein 51 (FKBP5), which binds to the GR to de-activate the 
receptor (100, 101). 
 
Figure 21. Schematic of HPA Axis. 
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 Improper regulation of Fkbp-5 or the HPA axis overall is implicated in a variety of 
neuropsychiatric disorders. Polymorphisms in Fkbp5 are associated with an increased risk for 
recurrent depressive episodes (102) and also with increased risk for development of post-
traumatic stress disorder (PTSD) (103). In the case of PTSD, polymorphisms result in enhanced 
induction of Fkbp5 and impairment of negative feedback leading to over activation of the GR 
(101). In fact, recent work demonstrated a link between the Fkbp5 polymorphism rs136078 and 
regulation of HPA axis reactivity (104). Furthermore, human patients with melancholic 
depression display an over activation of the HPA axis (105). In addition to depression, HPA axis 
dysfunction is also associated with diseases such as schizophrenia and PTSD (Reviewed in (98)).  
3.1.2  Programming of the HT by GCs During the Fetal Period 
Programming refers to the ability of non-genetic factors to cause permanent changes during the 
fetal period that eventually lead to stable changes in adult physiology (106). In fact, prenatal 
treatment with GCs such as Dex may alter the programming of the HT leading to alterations in 
adult functioning. Within the central nervous system, the HPA axis is considered to be 
vulnerable to programming, and as discussed above, dysregulation of the HPA axis is associated 
with a variety of neuropsychiatric conditions. Given the role of GCs in the HPA axis, it is not 
surprising that elevated levels of GCs during the fetal period are associated with predisposition to 
the development of neuropsychiatric conditions and altered stress reactivity (See §1.3 and (33)). 
In addition to changes in the HPA axis, there are also alterations in the hypothalamic-pitutary-
gonadal and growth hormone axes. In female mice, antenatal Dex treatment resulted in delayed 
puberty and irregular estrus cycles, potentially due to inhibition of gonadotropin-releasing 
hormone neurons in the HT or up-regulated production of gonadotropin-inhibitory hormone 
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(107). In rats, prenatal treatment with Dex resulted in decreased expression of growth hormone 
releasing hormone in the HT and increased fat accumulation in the liver (108). Interestingly, 
growth hormone axis function was found to be impaired only in the adult female offspring, not in 
the males (108).  
3.1.3 Sexually Dimorphic Action of Glucocorticoids 
Within the central nervous system, there are structural and genomic differences that may 
contribute to altered prevalence of neurological disorders. For example, microarray analysis in 
the adult mouse HT indicates sexually dimorphic expression patterns (109). In humans, structural 
differences within the brain are prevalent in young adults, indicating that sex differences in the 
connectome of the brain begin early in life (110). With regards to neurodevelopmental disorders, 
women have affective disorders at a rate twice that of males. Autism spectrum disorders also 
tend to occur at much higher rates in males than females. Furthermore, the onset of disorders 
such as schizophrenia and depression tend to occur at the same time as adolescence—a time 
when major sex-specific changes are occurring in the brain (111). In major depressive disorder, 
not only is there a higher prevalence in women, but also the action of the HPA axis differs 
between men and women. For example, only men display altered ACTH pulsatility whereas 
women tend to have higher levels of cortisol secretion (reviewed in (112)).  
In addition to sexually dimorphic prevalence of neurological disorders, there are other 
disorders displaying a male/female bias including rheumatoid arthritis, Cushing’s disease, and 
kidney diseases (113). Interestingly, these diseases all involve inflammatory processes; therefore, 
gender and the action of GCs may converge to contribute to the development of these diseases. 
Using male versus female rat liver cells, microarray analysis indicated gender-specific actions of 
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GCs resulting in distinct regulation of target genes depending on the sex (113). Therefore, it may 
be possible that gender prevalence of disorders linked to aberrant HPA axis function may have a 
basis in prenatal programming of the HT by GCs. In fact, some have suggested that the sexually 
dimorphic basis for diseases such as schizophrenia are rooted in abnormal development of 
sexually dimorphic areas of the brain associated with mood or HPA axis function (112).  
3.1.4 Long Lasting Consequences of GC Exposure  
Treatment with GCs during the fetal period is associated with long lasting changes in the 
structure of the brain, behavior, and stress reactivity (see §1.3). Several studies have assessed if a 
previous GC treatment can impact future GR mediated gene expression. For example, in rat 
hippocampal progenitor cells, Dex treatment results in specific demethylation of sites within the 
Fkbp-5 gene. This demethylation persists at twenty days after treatment indicating a permanent 
change such that the cells have a “memory” of hormone exposure (103). Notably, this 
differentially methylated site within Fkbp-5 in humans harbors not only three GREs, but contains 
a polymorphism associated with increased risk for the development of PTSD (103). Furthermore, 
synthetic GC exposure during the fetal period is associated with transgenerational changes in 
gene expression. To assess transgenerational changes in gene expression, rats were treated 
prenatally with Dex or vehicle (F0), reared, and then bred to create the F1 and F2 generations. 
Importantly, only the F0 generation was exposed to Dex, but genetic differences in both the F1 
and F2 generation were identified. For example, within the liver of the F1 animals, increased 
expression of Igf2 and H19, two imprinted genes, were observed, but Igf2 expression decreased 
in the F2 generation. Alterations in methylation of Igf2 were only noted in the F1 generation 
while H19 gene methylation was only affected in the F2. Notably, within only the F2 generation, 
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expression of imprinted genes depended on which parent was exposed to Dex. For example, if 
the father was exposed to Dex prenatally, in the F2 generation there was increased expression of 
H19 and other maternally expressed genes. Therefore, GC exposure can have long lasting 
impacts on gene expression and imprinting for multiple generations (114). However, these 
results must take into consideration that the pregnant females were injected with Dex or vehicle 
every day for a week. Within clinical practice, three or more courses of synthetic GCs in the 
prenatal period are associated within increased fetal death (25). Therefore, 7 doses of GCs may 
not adequately model human outcomes. These studies are particularly notable as during 
mammalian brain development, there are major changes in DNA methylation. For example, 
DNA methylation occurs at both CG and non-CG regions; although methylation in non-CG 
regions is initially low, it increases over developmental time (human childhood to adolescence) 
and predominates in mature neurons (115). Since Dex treatment can alter methylation status of 
genes such as Fkbp-5 (103), global changes in methylation due to GC exposure may lead to 
changes in gene expression and possible increased risk of disease.   
3.1.5 Rationale and Summary 
In spite of the crucial role for the HT in regulating a wide variety physiological processes, we are 
only now beginning to understand the molecular program underlying differentiation and 
maturation of the HT. Furthermore, as the number of individuals suffering from stress-related 
disorders increases, we are beginning to recognize the presence of sexually dimorphic responses 
to stress possibly due to sex specific differences in the development of the HT (100). Given the 
sexually dimorphic actions of GCs and their implications in programming the developing HT, we 
sought to determine the GR regulated transcriptome and male or female specific HT-NPSCs. 
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Previous work from others has demonstrated that NPSCs from the hypothalamus can be grown in 
culture as neurospheres and differentiated to form specific subtypes of neurons (116). RNA-Seq 
analysis of HT-NPSCs treated with Dex revealed the presence of distinct sex specific profiles of 
GR regulated gene expression. Candidates from the RNA-Seq analysis were further analyzed to 
ascertain if a previous GC exposure resulted in alterations of future GR transcriptional activity. 
We found sexually dimorphic long lasting effects on expression of Fkbp-5 and permanent 
alterations in GR regulation of H19 expression. Finally, preliminary data of HT-NPSCs 
previously exposed to Dex demonstrate an altered proliferative response, possibly due to changes 
in H19 and miR-675 regulation. Taken together, this study indicates that treatment with Dex 
results in long lasting, sexually dimorphic changes in HT-NPSC biology that may contribute to 
overall programming and function of the HT. 
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3.2 MATERIALS AND METHODS 
Mouse NPSC cultures: NPSCs were derived from E14.5 hypothalami of wild-type C57Bl/6 
mice grown as three-dimensional neurosphere cultures. Following harvest, cells were genotyped 
to ascertain presence of SRY to determine sex. Cells were passaged every seven days and 
experiments were performed at P3.  
 
RNA-Seq Library Preparation and Analysis: HT-NPSCs were treated with 100 nM Dex or 
Ethanol (vehicle) for a period of four hours. Cells were harvested in Trizol and RNAs isolated 
using the Machery-Nagel Nucelospin RNA II Kit. RNA-Seq library was generated according to 
manufacturer’s instructions using the TruSeq Stranded Total RNA Kit (Illumina, RS-122-2201). 
The library was then submitted to Tufts Genomics Core for next generation sequencing. 
Following sequencing, the reads were assessed for quality using a FastQC tool. The reads were 
then mapped to the mm9 version of the mouse genome using tophat2 and the technical replicates 
merged. Cuffdiff was run with the default parameters on these samples to find the differentially 
expressed genes in FPKM values, then further refined to only contain genes induced by Dex by 
greater than 1.5 fold. The bam files were submitted to GEO (accession # GSE55113). 
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Dex Programming Experiments: P1 neurospheres were cultured for 6 days after passaging (3 
days after replenishment with fresh epidermal growth factor and fibroblast growth factor-1) and 
treated for a period of 24 hours with 100nM Dex (Sigma Chemicals, St. Louis, MO) or vehicle 
(EtOH). Following treatment, cells were passaged using standard conditions and grown for an 
additional two weeks. P3 neurospheres were then re-treated with Dex for 4 hours (for 
protein/RNA studies) or 24 hours for BrdU incorporation analysis at 6 days post passaging and 
harvested (Figure 22).  
 
 
Figure 22. Schematic of in vitro programming experiments. 
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Quantitative Real Time-PCR (qRT-PCR): P3 previously Dex/EtOH treated neurospheres 
were re-treated with Dex or ethanol for 4 h and were harvested in Trizol and processed for RNA 
isolation using the Machery-Nagel Nucelospin RNA II Kit. For samples that were to be analyzed 
for miR-675, a standard precipitation method was used to isolated RNA to preserve the small 
RNA species. cDNA synthesis was performed using iScript Select cDNA Synthesis Kit (Bio Rad 
#170-8897). qRT-PCR reactions were performed on a BioRad CFx qRT-PCR machine using 
iTaq Universal SYBR Green Supermix (Bio Rad #172-5121) and primers with efficiencies 
calculated to be greater than 80%.  
 
NPSC BrdU Assays: Passage 3 neurospheres were treated with 100nM Dex (Sigma Chemicals, 
St. Louis, MO) or vehicle (Ethanol) for 24 hours. During the last 4 hours of Dex treatment, 
10uM Bromodeoxyuridine (BrdU) (Sigma Chemicals, B-9285) was added. Neurospheres were 
then dissociated into single cells and attached to poly-D-lysine treated coverslips prior to fixation 
with 4% paraformaldehyde. Fixed cells were processed for immunocytochemistry using standard 
methods. A rat anti-BrdU antibody (Abcam, ab6326) was used at 1:500 and Anti-Rat Alexa 
Flour 488 (Invitrogen, A21208) at 1:1000. Images were captured using a Nikon Eclipse E400 
Microscope and Photometrics Cool Snap E52 camera.  
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3.3 RESULTS 
3.3.1 Sexually Dimorphic Action of the GR in HT-NPSCs 
To determine if Dex treatment of HT-NPSCs results in patterns of sexually dimorphic gene 
expression, we performed RNA-Seq analyses. Analysis of protein coding genes that were 
regulated by at least 1.5 fold revealed 224 genes regulated in common and almost twice as many 
female specific genes than male specific genes (Figure 23B). This result is consistent with the 
distribution of male/female specific genes reported in the liver by (113). The female specific 
genes also tend to be repressed in response to Dex treatment (Figure 23C). Interestingly, one of 
the most highly regulated genes in both datasets was Cftr (see §2.4.2). We also observed the 
male specific regulation of Gjb6 (see §2.4.2 and §2.6). Within the female data set we observed 
repression of Rxrg, a gene associated with despair and depressive behaviors and changed in 
serotonin signaling in mice (117). Other notable targets and their functions are represented in 
Table 4.  
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Figure 23. Dex treatment of HT-NPSCs results in sexually dimorphic patterns of gene expression. 
A. Heat map representing gene expression in response to 4 hour Dex treatment. B-C Refinement 
of expression data indicates a subset of genes regulated by GR in both sexes, and distinct subsets 
of male and female specific genes.  
 
Table 4. Select candidates revealed in RNA-Seq analysis of HT-NPSCs 
Gene Name Induced/Repressed Male/Female Function 
Fkbp-5 Induced Both Negative regulator 
of GR 
Rxrg Repressed Female Only Associated with 
despair and 
hedonistic behaviors 
in mice  
H19 Induced Both Long non-coding 
RNA, encodes miR-
675, roles in 
proliferation and 
differentiation 
Ada Induced Both, higher in females CDK2 Regulator, 
role in cell cycle 
Cftr Induced Both, higher in males Ion channel, 
implicated in cystic 
fibrosis 
Gjb6 Induced Male Only Gap junction protein, 
involved in blood 
brain barrier 
regulation 
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Following initial analysis of the protein coding RNA-Seq dataset, the list of male and 
female specific genes was loaded into IPA. In both the male and female datasets, the number one 
network was comprised of cell cycle regulatory genes (Figure 24).  Interestingly, the constituents 
of each of these cell cycle networks is different between the two sexes (Figure 24). Therefore, 
Dex regulated alterations in proliferation between the two sexes likely occur through distinct 
mechanisms.  
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Figure 24. Cell cycle regulatory networks are highly enriched in both male and female datasets, but 
vary in their constituents. 
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 IPA analysis using lists from Dex regulated genes in female (A) and male (B) HT-NPSCs define 
the distinct cell cycle networks shown. Upregulated genes are depicted in red and downregulated 
genes in green. The shading of red and green symbols indicates the extent of Dex upregulation or 
downregulation, respectively. 
 
Based on the top candidates identified from the RNA-Seq analysis (Table 4) we then 
tested if any of these genes demonstrated long term alterations in GR gene regulation. Given the 
role of Fkbp-5 in regulating GR and implications for Fkbp-5 polymorphisms in HPA axis 
dysfunction, we first sought to determine if future regulation of Fkbp-5 by GR is altered by a 
previous exposure to Dex. In male cells, pre-treatment with Dex (see methods section), has no 
effect on P3 expression of Fkbp-5 (Figure 25A). However, in female cells, a previous exposure 
to Dex results in attenuated activation of Fkbp-5 in response to Dex (Figure 25A). Interestingly, 
term-born human females, but not males, treated prenatally with synthetic GCs go on to have 
altered stress responsiveness and secrete higher levels of cortisol in response to stress (33). 
Therefore, alterations in GC-mediated expression of Fkbp-5 in the HT may contribute to this 
altered stress reactivity later in life. Although the induction of Fkbp-5 by Dex is only altered in 
the females, it is interesting to note that both sexes display alterations in baseline expression of 
Fkbp-5 (Figure 25B).  
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 Figure 25. Fkbp-5 is subject to sexually dimorphic long lasting changes in GC-regulated expression. 
A. Cells either naïve or previously exposed to Dex for 24 hours (Pre-Treated) were treated with 
100nM Dex at P3, and expression of Fkbp-5 analyzed. Pre-treatment of male cells had no effect 
of Dex treatment whereas female cells demonstrate less induction of Fkbp-5 when compared to 
controls. B. Baseline values of Fkbp-5 relative to GAPDH are altered in both male and female 
cells previously exposed to Dex. n=3 biological replicates per sex, One-way ANOVA with 
Tukey’s Post-Test, * represents p<0.05, ** represents p<0.01. 
3.3.2 Long Lasting Alterations in GC-Regulated Activity in HT-NPSCs 
One of the Dex-regulated genes identified in our RNA-Seq analysis was the long intergenic non-
coding RNA, H19. H19 is a maternally imprinted gene that is highly expressed during embryonic 
development and harbors two highly conserved miRNAs, miR-675-3p and miR-675-5P. These 
miRNAs are implicated in both regulation of stem cells proliferation and also skeletal muscle 
differentiation (46, 118). Given the interesting biology of H19 and the role of miR-675 in 
regulating stem cell proliferation, we next sought to determine if H19 expression was altered in 
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response to an early treatment with Dex. In both male and female cells that were not treated at 
P1, a Dex treatment at P3 results in a 2-fold increase in H19 mRNA expression (Figure 26A). 
Surprisingly, in cells pre-treated with Dex at P1, upon re-treatment with Dex at P3, H19 is no 
longer induced, but repressed by 0.5 fold (Figure 26A). Although we see the same phenomenon 
in both male and female cells, analysis of baseline expression of H19 revealed that only female 
cells revealed alterations in basal expression of H19 (Figure 26B). 
 
  
 
Figure 26. Pre-treatment with Dex leads to long lasting alterations in GR mediated regulation of H19. 
A. Cells either naïve or previously exposed to Dex for 24 hours (Pre-Treated) were treated with 
100nM Dex at P3, and expression of H19 analyzed. Cells of both sexes demonstrate that pre-
treated with Dex results in GC mediated transcriptional repression instead of activation. B. 
Baseline values of H19 relative to GAPDH are altered in only female cells previously exposed to 
Dex. n=3 biological replicates per sex, One-way ANOVA with Tukey’s Post-Test, ** represents 
p<0.01 and *** represents p<0.001. 
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Since H19 is induced in HT-NPSCs, we next determined if there was any GR-regulated 
induction of miR-675. Preliminary data from our RNA-Seq analysis indicates an increased 
number of reads in the region of H19 that contains miR-675, and that they may be induced in 
response to Dex (Figure 27).  
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 Figure 27. miR-675 may be Dex regulated in HT-NPSCs. 
Read data from representative male/female samples from each treatment group were loaded into 
Integrative Genome Viewer (IGV). As shown by the grey boxes, there are increased reads at 
both miR-675-3P (Region 1) and miR-675-5P (Region 2) in both male and female cells treated 
with Dex.  
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miR-675 is harbored within exon 1 of H19 and gives rise to two distinct miRNAs, miR-
675-3P and miR-675-5P. Although collectively miR-675 and H19 are associated with tumor 
suppression, each individual miRNA can have a stronger anti-proliferative effect depending on 
the cell line. For example, miR-675-5P decreases proliferation in embryonic stem cells whereas 
in mouse embryonic fibroblast cells, the 3P form has a greater antiproliferative effect (46). Since 
preliminary data indicate that both forms of miR-675 may be upregulated in HT-NPSCs in 
response to a 4 hour Dex treatment, we next determined if BrdU incorporation and therefore 
proliferation were altered in HT-NPSCs previously exposed to Dex. The anti-proliferative effects 
of Dex are well documented (29, 36, 56), but it is not known if a previous exposure to Dex can 
impact future proliferation. Preliminary data indicate that in cells that were previously treated 
with Dex, there is a much greater anti-proliferative response to a P3 Dex treatment (Figure 28). 
Although a decrease in proliferation is noted among all samples, only cells previously treated 
with Dex demonstrate a statistically significant response. Interestingly, in only the female cells, 
previous exposure to Dex results in a significant increase in BrdU labeling under baseline 
conditions (Figure 28). This result is particularly interesting since female, but not male cells, 
have elevated baseline levels of H19 in response to a previous treatment with Dex (Figure 26).  
 95 
 Figure 28. Pretreatment with Dex results in enhanced anti-proliferative effect at P3 
Female or male HT-NPSCs were treated with Dex or vehicle (Ethanol; EtOH) for 24 h and 
pulsed with BrdU during the four hours of treatment. Immunocytochemistry was performed to 
detect BrdU positive nuclei.  Shown are three independent coverslips per sex counted to 
ascertain the percentage of cells that passed through S-phase (i.e. BrdU positive nuclei). Error 
bars represent SEM, n=1 biological replicate per sex. One-way ANOVA with Tukey’s post test, 
p<0.01. 
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To determine if alterations in Dex responsiveness at P3 in cells previously exposed to 
GCs were the result of changes in GR expression, we next sought to determine if a pre-treatment 
with Dex resulted in changes in GR mRNA or protein levels. Previous exposure of HT-NPSCs to 
Dex resulted in no change in the mRNA expression of GR at P3 (Figure 29). Preliminary 
analysis of GR protein also indicated no change in GR expression in P3 HT-NPSCs previously 
exposed to Dex (Data not shown). Therefore, alterations in regulation of Fkbp-5 and H19 may be 
due to alterations in function/recruitment of the receptor or epigenetic changes (see discussion 
§3.4).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 29. Pre-treatment with Dex results in no change in GR mRNA expression at P3. 
A. Cells either naïve or previously exposed to Dex for 24 hours (Pre-Treated) were treated with 
100nM EtOH vehicle at P3, and expression of GR relative to GAPDH analyzed. No difference in 
baseline expression of GR mRNA was detected in either sex. n=3 biological replicates per sex. 
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3.4 DISCUSSION 
Neuropsychiatric disorders related to dysfunction of the HPA axis cost Americans a significant 
amount of money, with the economic burden of depression alone reaching an estimated cost of 
$83.1 billion in 2000 (119). Therefore, understanding their neurodevelopmental basis may 
prevent these disorders or lead to more effective treatment options, improving quality of life and 
decreasing overall economic burden. The influence of GC programming on the HT, and 
specifically sexually dimorphic effects of GCs may further yield additional insights into the basis 
for these diseases. In this chapter, we used HT-NPSCs to identify sexually dimorphic GR target 
genes, and then assessed the long-term impact of GC treatment on gene expression. We 
identified that Dex-induced expression of Fkbp-5 is attenuated only in female cells. Furthermore, 
the long intergenic non-coding RNA, H19, is no longer Dex-induced in HT-NPSCs previously 
exposed to Dex but transcriptionally repressed. Given the role of miR-675 in regulation 
embryonic stem cell proliferation, changes in H19 and consequently miR-675 may explain the 
alterations in proliferation seen in HT-NPSCs previously exposed to Dex. Therefore, exposure of 
HT-NPSCs to Dex treatment can lead to sexually dimorphic persistent changes in gene 
expression that impact NPSC function.  
3.4.1 GC Treatment Results in Sexually Dimorphic Gene Expression 
Our RNA-Seq analysis revealed the presence of distinct GR regulated genes for each sex, 
and a set of 224 genes that were regulated in both sexes. As shown in Table 4, some of these co-
regulated genes like Cftr are expressed to different extents in male versus female cells 
demonstrating that sexually dimorphic actions of GR are not limited to expressed/not expressed. 
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Notably, there are approximately twice as many female specific genes as male specific genes—
which is consistent with studies performed in the liver (113). However, there were significantly 
more genes in each class identified within the liver (i.e. 4293 female specific genes in the liver 
vs. 123 in the hypothalamus), which may be indicative of fundamental differences between the 
liver and hypothalamus. Further analysis of our RNA-Seq data set using IPA demonstrated that 
in both male and female HT-NPSCs, the most highly regulated network formed by each involved 
the cell cycle. However, the cell cycle regulatory genes for each of the male/female cells varied 
extensively. Therefore, the regulation of cell cycle relies on sexually dimorphic pathways, and 
may contribute to differences in HPA axis development/function.  
3.4.2 Long Lasting Changes in GC Regulated Genes   
FKBP5 is an important regulator of the GR, involved in a negative feedback loop to resolve GR 
activation. Increased activity of GR and/or polymorphisms in Fkbp5 impacting its function can 
lead to dysfunction of the HPA axis. In HT-NPSCs, we observe long lasting changes in GR 
regulated expression of Fkbp5 in female cells only. In female HT-NPSCs previously exposed to 
Dex, future Fkbp5 transcriptional induction by Dex is attenuated. Less induction of Fkbp5 may 
then lead to an inability to resolve the stress response. In fact, in a study of term born children, 
female infants exposed to GCs during the fetal period exhibited much higher levels of salivary 
cortisol in response to a stressful situation (33). Therefore, the elevated levels of cortisol 
specifically in the female children may be the result of a sex specific effects on regulation of 
Fkbp5 within the hypothalamus. There may also be altered regulation of Fkbp5 in other tissues, 
and future experiments could ascertain if this sex specific programming exists exclusively within 
the HT.   
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Fkbp5 contains a polymorphism associated with PTSD located in a differentially 
methylated region within a trio of GREs residing in intron 7. Notably, data mining of publically 
available DNAse hypersensitivity studies indicates a region of open chromatin within intron 7 of 
Fkbp5 that exists only within the adult mouse brain (See Appendix, Figure 31). Changes in the 
chromatin status during embryonic development may disturb the presence and location of these 
hypersensitive sites, therefore changing the transcriptional activity of that gene. For example, 
treatment of hippocampal progenitor cells with Dex results in demethylation within intron 7 of 
Fkbp5. The decreased in methylation at intron 7 results in less induction of Fkbp5 by GR—
similar to the memory effect we see in HT-NPSCs (103). Taken together, alterations in 
chromatin status triggered by treatment with Dex lead to sex-specific aberrant regulation of 
Fkbp5. This altered regulation of Fkbp5 within the HT may contribute to the development of 
abnormalities in HPA axis regulation. Bisulfite sequencing of intron 7 of Fkbp5 in male/female 
specific HT-NPSCs pre-treated with Dex will indicate if changes in methylation are sexually 
dimorphic. Additional genomic experiments such as DNase hypersensitivity assays and RNA-
Seq experiments in pre-treated HT-NPSCs will yield important insight into the mechanisms 
behind long lasting changes in gene expression and other susceptible genes.  
We also observed changes in the basal mRNA expression of Fkbp5, although we have yet 
to assess protein levels of FKBP5. In both male and female cells, pre-exposure to Dex resulted in 
elevated baseline levels of Fkbp5. Since FKBP5 directly binds to GR in the cytoplasm of cells to 
maintain its inactive conformation by decreasing ligand binding and impeding translocation to 
the nucleus, alterations in its baseline levels may impede the ability of GR to activate. Additional 
experiments examining the activation of the receptor and its ability to translocate to the nucleus 
in HT-NPSCs previously exposed to Dex would indicate if overall GR activation is impaired in 
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cells previously exposed to hormone. Since GR resistance (i.e. the inability of GR to respond to 
high levels of cortisol) is another hallmark of mood disorders (120), changes in the activation of 
the receptor due to early programming of HT-NPSCs may also be a contributing factor to altered 
HPA axis. 
Previous work indicated that the expression of H19 was undetectable in the fetal mouse 
brain (46). Since we see an induction of H19 in response to Dex treatment within HT-NPSCs, 
and the HT comprises a very small portion of the brain overall, this may indicate that H19 is 
specifically expressed only within the HT. Therefore, H19 or miR-675 may serve a very specific 
function within the developing HT. Future experiments using in situ hybridization to assess the 
expression of H19 will yield insight into both the extent of expression within the developing 
brain and also the time points at which it is expressed. miR-675 is implicated in a wide variety of 
cellular processes such as proliferation and differentiation all of which are important to proper 
hypothalamic development. Preliminary data from our RNA-Seq study indicates that miR-675 
may also be Dex regulated in HT-NPSCs. However, additional experiments such as northern 
blotting or qRT-PCR are necessary to confirm that the reads seen in the region of H19 where 
miR-675 is located are true reads. 
In both male and female cells, H19 is induced by Dex approximately 2 fold. 
Provocatively, a pre-exposure to Dex results in transcriptional repression instead of activation. 
Since H19 harbors miR-675, expression of the miRNAs and their functionality may also be 
altered. In HT-NPSCs previously exposed to Dex, we observed changes in BrdU incorporation. 
In both male and female cells, we see an enhanced proliferative response to Dex treatment. 
Preliminary data indicate that female untreated cells demonstrate ~2% decrease and untreated 
cells a 5% decrease compared to a ~10% decreases in labeling seen in both sexes pre-treated 
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with Dex. In female cells alone, we see an increase in basal levels of H19 and BrdU labeling. 
These results are counterintuitive because we would predict that if miR-675 is mediating these 
proliferative effects, the increased expression of H19 at basal levels in the female HT-NPSCs 
would lead to decreased basal proliferation. Furthermore, if H19 is less induced in response to 
Dex, we would predict that there would be less of a proliferative response not an enhanced 
response. This may be explained because miR-675-3P and miR-675-5P, although both are 
associated with anti-proliferative response, have different affects depending on the cell type. For 
example in embryonic stem cells, miR-675-5P is the primary driver of the anti-proliferative 
response (46). Furthermore, GR is known to regulate a wide variety of cell cycle regulators such 
as Cyclin-D1 (36) and the control of proliferation is likely to involve a wide variety of different 
components. As shown by IPA analysis, in HT-NPSCs, male versus female cells each have their 
own distinct networks of genes involved in cell cycle regulation. Since each sex has different GR 
regulated genes that contribute to its regulation of cell proliferation, this may explain why we 
only detect changes in basal levels of proliferation female HT-NPSCs.   
3.4.3 Summary 
In summary, GC treatment of HT-NPSCs generates sexually dimorphic patterns of gene 
expression, and long-term consequences on gene expression and NPSC function. RNA-Seq 
analysis indicated the existence of female and male specific classes of genes. Further analysis of 
Fkbp5 indicated that in female HT-NPSCs, previous exposure to Dex result in alterations in later 
expression of Fkbp5. Therefore, changes in Fkbp5 may contribute to future alterations in GR 
signaling and HPA axis response in the future. Regulation H19 also demonstrated long-lasting 
changes in GC-mediated gene expression in HT-NPSCs previously exposed to Dex. Alterations 
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in H19 and its cognate miRNA, miR-675 may contribute to changes in proliferation seen in pre-
treated HT-NPSCs.  These changes in gene regulation may be due to alterations in chromatin 
status within these genes. Taken together, treatment with Dex causes a wide variety of changes 
in HT-NPSCs that may contribute to future abnormalities in the HPA axis.    
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4.0  DISCUSSION 
4.1 SUMMARY OF FINDINGS 
The use of GCs in decreasing mortality in premature babies is undisputed, but the neurological 
side effects are increasingly apparent (4, 32-34). Although the exact causes of these deficits are 
still not clear, this work revealed additional insights into how GCs could impact the developing 
brain through detailed mechanistic studies of GR signaling within CC-NPSCs and an 
examination of sex specific effects on programming of HT-NPSCs. In CC-NPSCs, we uncovered 
a new role for Cav-1 in mediating the genomic effects of GR. In the Cav-1 KO we also observed 
a lack of anti-proliferative response to Dex treatment, which may be due to changes in 
expression of Sgk1 in the Cav-1 KO CC-NPSCs. In addition to Sgk-1, loss of Cav-1 also resulted 
in the altered regulation of approximately 100 other GR-regulated genes. Alterations in GR-
regulated gene expression may be due to changes in the phosphorylation of GR and its 
recruitment to target genes. In HT-NPSCs, we identified sexually dimorphic classes of GR 
regulated genes. Since the HPA axis and prevalence of diseases related to the HPA axis is 
sexually dimorphic (see §3.1.3), these distinct classes of GC regulate genes may underlie overall 
differences in the development and function of the HPA axis. We also identified a subset of 
genes that are susceptible to long lasting programming effects of GCs in HT-NPSCs. Previous 
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exposure to Dex resulted in persistent changes in the regulation of GR target genes such as 
Fkbp5 and H19. The implications for these findings are discussed below. 
4.2 CAV-1 MEDIATED CROSSTALK BETWEEN RAPID AND GENOMIC GR 
SIGNALING 
Although both rapid and genomic GR signaling exists in NPSCs, it is not clear what the 
individual contribution of each is for negative neurodevelopmental outcomes of antenatal GCs. 
In §2, we identified a role for Cav-1 in mediating crosstalk between genomic and rapid GR. 
Given the importance of Cav-1, this may indicate a new pharmacologic target for manipulating 
the levels of genomic or rapid GR signaling. For example, let’s consider a hypothetical scenario: 
Cav-1 KO animals exposed to Dex and delivered prematurely via C-section are no different than 
their wild-type counterparts in terms of their ability to breathe. This result would potentially 
indicate that Cav-1 dependent GC signaling may not be essential for the pulmonary benefits and 
be more of a factor in neurodevelopment consequences or programming effects. Therefore, if 
this hypothetical scenario were true, it may be beneficial to pharmacologically target Cav-1 using 
a compound such as incadronate (121) to keep the beneficial pulmonary benefits of synthetic GC 
use in the fetal period while mitigating negative effects on neurodevelopment. Since Cav-1 KO 
animals are viable and have functioning caveolae, this may be a low risk way to minimize 
negative side effects of synthetic GC use. Conversely, if in our hypothetical scenario the Cav-1 
KO animals treated prenatally with Dex and delivered prematurely died shortly after birth from 
respiratory distress syndrome indicating that Cav-1 mediated GC signaling is essential for 
maintaining the pulmonary benefit, specifically targeting Cav-1 would not be beneficial. 
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However, further analysis of the ~100 genes identified in this study may indicate molecular 
candidates critical for the pulmonary benefit that could then be pharmacologically targeted. 
Therefore, further study of Cav-1 KO animals and their response to prenatal Dex, in conjunction 
with additional study of the gene targets presented in this study may indicate more specific 
pharmacological intervention.  
4.3 SEXUALLY DIMORPHIC GC RESPONSES IN THE HT 
In HT-NPSCs, unique sexually dimorphic profiles were revealed in response to Dex treatment, 
some of which were susceptible to sex-specific programming effects. Given the altered 
prevalence of disorders relating to HPA axis regulation in males versus females (See §3.1.3), 
differences in the development of the HT may be a contributing factor. This result complements 
current discussions within the medical community related to sex-specific recommendations in 
dosing for adults. In fact, women are 50-75% more likely to have an adverse reaction to a drug 
response due to greater sensitivities to medicine possibly linked to differences in metabolism, 
clearance, and absorption (122). This is especially important given that in a 2012 study, term 
born females exposed to GCs in the fetal period had elevated levels of cortisol in response to a 
stressful situation (33). Therefore, sex of the fetus needs to be of greater concern before treating 
with antenatal steroids, and in future studies assessing differences in brain structure or behavior 
in response to a pre-natal exposure to GCs.  
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4.4 REACHING AN IMPROVED THERAPY: WHAT CAN THIS WORK TELL US 
ABOUT ANTENATAL USAGE OF DEXAMETHASONE V. BETAMETHASONE? 
Within clinical practice, antenatal GCs are prescribed either as two courses of Beta given 24 
hours apart, or four doses of Dex given 12 hours apart (27). Although upon initial glance the two 
GCs appear functionally equivalent, differing only in the isomeric positioning of one methyl 
group, the functionality of these two hormones varies significantly and current studies reveal no 
consistently “better” GC for antenatal use (Reviewed in (27)). For example, in mice, Beta 
induced greater lung maturation with less growth restriction than Dex. However, these studies 
are all performed in vivo and examined physiological changes like lung maturation or fetal heart 
rate, and not the underlying molecular mechanisms for these affects. In order to reach improve 
therapies, we need a better understanding of the molecular basis for these effects. As shown in 
Chapter 3, Dex treatment of HT-NPSCs can cause long lasting programming of certain genes.  Is 
this a Dex specific phenomenon? Similar experiments using Beta, or other GCs may indicate if 
some are more likely than others to cause long lasting changes in GR regulated genes. 
Furthermore, as discussed in §4.3 fundamental differences between males and females lead to 
different response to pharmacological interventions. Preliminary work from our lab indicates that 
induction of genes such as Cftr, Fkbp5, and Gjb6, vary both in their response to GC and 
differences between the sexes. In male CC-NPSCs, all three genes are induced to a greater extent 
when treated with an equivalent dose of Beta instead of Dex. In contrast, female CC-NPSCs, 
actually have a reduced response when treatment with Beta instead of Dex (Anthony Rudine, 
Personal Communication). In term born children treated during the fetal period with GCs, the 
authors noted no difference in cortisol reactivity if the child was treated with Dex or Beta (33). 
However, in spite of reporting sexually dimorphic changes in cortisol secretion, the authors did 
 107 
not separate the Dex/Beta treated groups by sex prior to analysis. Therefore, it may be possible 
that treating with different GCs may change overall programming of NPSCs.  
Strikingly, although Beta and Dex have similar affinities for the GR and similar genomic 
potencies, Dex has a 5-fold greater potency for the rapid action of GR than Beta in rat 
thymocytes (26).  As discussed previously (§4.2), different GR signaling modalities may exert 
discrete influences on neurodevelopment and/or pulmonary benefits. Therefore, if rapid signaling 
was gives rise to more severe neurodevelopmental abnormalities, but the genomic action of GR 
is needed for pulmonary benefits, the use of Beta instead of Dex is indicated. Furthermore, there 
are other clinically relevant GCs, each of which has different genomic and rapid potencies. For 
example, Prednylidene has a 13-fold greater rapid potency than Beta and 2.5-fold greater rapid 
potency than Dex compared to 7-fold less potent than both for genomic effects (26).  Therefore, 
use of Prednylidene may be indicated if rapid and not genomic activation of GR is required. 
However, further studies on the in vivo potencies and potencies in different cell types are also 
needed, as the numbers mentioned refer to one particular cell type and they may not be exactly 
applicable to NPSCs.  
 Furthermore, the programming effect seen in HT-NPSCs may be the result of a genomic 
or rapid GR signaling, or both. Exposing NPSCs to GCs with different genomic or rapid 
potencies may yield insight into which GCs cause a larger programming effect. Since loss of 
Cav-1 ablation changes the Dex regulated transcriptome, treating Cav-1 KO NPSCs with Beta or 
other GCs may result in GR mediated regulation of a different subset of genes. Comparing the 
Beta vs. Dex regulated profiles in the Cav-1 KO NPSCs, will yield additional insights into the 
functional genomic consequences of using one GC versus the other. 
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4.5 CONCLUDING REMARKS 
Each chapter of this thesis examined very distinct roles for GR in neurodevelopment. However, 
each of the new insights presented in Chapters 2 and 3 into GR action in NPSCs leads to 
complementary questions. For example, does the role of Cav-1 in mediating crosstalk between 
the rapid and genomic actions vary depending on the region of the brain in question or the sex? If 
a similar microarray was performed in Cav-1 KO HT-NPSCs, would we see similar altered 
regulation of the same target genes identified in CC-NPSCs? In HT-NPSCs, we see lasting 
changes in Dex-mediated gene transcription—would we see these changes in Cav-1 KO NPSCs? 
Phosphorylation of the GR, particularly at S211, was shown to be important in CC-NPSCs. Does 
phosphorylation of GR vary at this site or others in different sexes or in response to treatment 
with different GCs? Are different phosphorylation sites more or less important in different 
regions of the brain? What about sex specific gene regulation? Will the profile we see in the HT 
be applicable to all regions of the brain? Finally, what do these each of these questions mean in 
terms of antenatal GC action in vivo?  Taken together, this thesis revealed novel insights into GR 
signaling in CC-NPSCs and sexually dimorphic and persistent changes in hypothalamic gene 
expression. This new knowledge may lead to improved antenatal GC therapies that maximize 
therapeutic benefit while minimizing neurodevelopmental complications.  
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APPENDIX A 
SUPPLEMENTAL IGV FIGURES 
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 Figure 30. DNAse hypersensitivity assays in E14.5, E18.5 and adult mouse brain indicate 
developmentally dynamic changes in chromatin status within Cftr. 
Each of the red boxes highlights DNAse sensitive regions within Cftr. Region 1 is sensitive to 
treatment at all time points. Region 2 however is only in an open conformation at E14.5, and not 
E18.5 or in the 8 week old adult. However, in Region 3, the hypersensitive site only exists in the 
adult animal, not at E14.5 or E18.5 Shown are 2 biological replicates from E14.5 and E18.5 and 
7 8 week old adult C57/BL6 animals. Data accessible using GEO # GSM1014151.  
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Figure 31. DNAse hypersensitivity assays in E14.5, E18.5 and adult mouse brain indicate that the 
region within intron 7 of Fkbp-5 is only open in the adult brain.  
Each of the red boxes highlights DNAse sensitive regions within Fkbp-5. Regions 1 and 3 are 
sensitive to treatment at all time points. Region 2, which is located within intron 7, however is 
only in a hypersensitive state in the adult animal, not at E14.5 or E18.5. Shown are 2 biological 
replicates from E14.5 and E18.5 and 7 8 week old adult C57/BL6 animals. Data accessible using 
GEO # GSM1014151. 
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